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Antipsychotic treatment of schizophrenia is often accompanied by distressing adverse effects and a 
high relapse rate. Although pharmacogenetic research has identified some promising candidate 
pharmacogenes, these remain poorly characterized in South African (SA) populations. This study 
investigated whether polymorphisms in several candidate pharmacogenes (COMT, CYP1A2, 
CYP2D6, DRD2, DRD3, HTR2A and SOD2) were associated with antipsychotic treatment outcome in 
a SA schizophrenia cohort.  
The cohort utilized consisted of 103 first episode schizophrenia (FES) patients from SA Coloured, 
Caucasian and Xhosa populations, clinically well-characterized and treated with a first generation 
antipsychotic, flupenthixol decanoate, for at least twelve months. Previously generated exome 
sequencing data of eleven of the FES patients were used to identify known and novel functional 
variants within the seven pharmacogenes, and the predicted functional effect of novel variants were 
assessed with SIFT and PolyPhen-2 algorithms. Based on these analyses and mining of the literature, 
a total of 33 variants were prioritized for genotyping by PCR-RFLP, long-range and allele-specific 
PCR, and TaqMan
®
 assays. Minor allele frequencies in our cohort were compared to populations 
from the 1000 Genomes Project or the Human CYP Allele Nomenclature databases to distinguish 
unique genetic variation in SA populations. A mixed model for repeated measures analysis was used 
to determine whether any of the polymorphisms identified were associated with antipsychotic 
treatment response, as measured by a change in PANSS scores over time from the twelve-month 
longitudinal PANSS scores adjusted at baseline. Inheritance models to estimate the effect size (ES) of 
significant associations were assessed using 95% confidence intervals (CI). 
Exome data revealed a total of eighteen functional variants in six of the genes, predominantly present 
in CYP2D6. Novel variants were identified in COMT (rs373611092) and SOD2 (rs372173830), 
where rs373611092 was predicted to “damage” the COMT protein function (SIFT score = 0.015). Of 
the 33 variants, only variants in COMT and DRD2 were significantly associated with changes in 
PANSS negative scores after twelve months of treatment. Associations with improved treatment 
outcomes included COMT rs4633 [P = 0.0080 (T allele), ES = -0.17 95% CI (-0.30 to -0.04)], and 
DRD2 rs1799732 [P = 0.0004 (-C vs CC), ES = -0.19 95% CI (-0.38 to 0.00)]. COMT haplotypes 
(rs2020917-rs737869-rs6269-rs4633-rs9332377) also showed an improved treatment outcome for 
negative symptoms. Undesirable treatment outcomes were associated with COMT rs9332377 [P = 
0.0006 (T allele), ES = 0.25 95% CI (0.11 to 0.39)], and DRD2 variants rs1799732 [P = 0.0004 (-- vs 
CC), ES = 0.50 95% CI (0.15 to 0.86)] and rs1079597 [P = 0.0020 (AA vs AG+GG), ES = 0.93 95% 
CI (0.34 to 1.53)].  
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This study confirmed the presence of unique variation in a SA FES cohort associated with 
antipsychotic pharmacogenetic traits, highlighting the value of re-sequencing in SA individuals. 
Several SNPs in COMT and DRD2 were identified to be involved in treatment response, specifically 
influencing negative symptoms. These results serve as a platform for future antipsychotic 
pharmacogenetic studies within the SA context that could aid the optimization of antipsychotic 
treatment in the uniquely diverse, but understudied populations.  




Antipsigotikumbehandeling vir skisofrenie gaan dikwels gepaard met ernstige negatiewe uitwerkings 
en ’n hoë terugvalkoers. Hoewel farmakogenetiese navorsing op ’n paar belowende 
kandidaatfarmakogene dui, is dit tot dusver nog swak getipeer onder Suid-Afrikaanse populasies. 
Hierdie studie het ondersoek ingestel na die verwantskap tussen polimorfismes in verskillende 
kandidaatfarmakogene (COMT, CYP1A2, CYP2D6, DRD2, DRD3, HTR2A en SOD2) en die uitkoms 
van antipsigotikumbehandeling by ’n kohort Suid-Afrikaanse skisofreniepasiënte.  
Die studiekohort het uit 103 skisofreniepasiënte met ’n eerste episode (sogenaamde FES-pasiënte) uit 
die Suid-Afrikaanse bruin, wit en Xhosa-bevolkingsgroepe bestaan. Die pasiënte is almal klinies 
goed getipeer en het reeds minstens 12 maande se behandeling met ’n eerstegenerasie-
antipsigotikum, flupentiksol-dekanoaat, voltooi. Eksoomvolgorededata wat voorheen vir 11 van die 
FES-pasiënte verkry is, is gebruik om bekende én nuwe funksionele variante in die sewe 
farmakogene te identifiseer, en die voorspelde funksionele uitwerking van nuwe variante is met 
behulp van SIFT- en PolyPhen-2-algoritmes beoordeel. Op grond van hierdie ontledings en 
literatuurontginning is altesaam 33 variante vir genotipering met PKR-RFLP-, langreeks- en 
allelspesifieke PKR, en TaqMan
®
-toetse uitgewys. Alleelfrekwensies in die studiekohort is met 
populasies uit die projek “1000 Genomes” en die databasis van die alleelnomenklatuur vir menslike 
CYP gene vergelyk om unieke genetiese variasie by Suid-Afrikaanse populasies te bepaal. ’n 
Gemengde model van herhaaldemetingsontleding is gebruik om vas te stel of enige van die 
geïdentifiseerde polimorfismes verband hou met die reaksie op antipsigotikumbehandeling, soos wat 
geblyk het uit ’n verandering in PANSS-tellings oor tyd vergeleke met die longitudinale PANSS-
tellings oor 12 maande wat op die basislyn aangepas is. Oorerwingsmodelle om die 
uitwerkingsgrootte (UG) van beduidende verwantskappe te bepaal, is met behulp van 
vertrouensintervalle (VI’s) van 95% beoordeel. 
Eksoomdata het altesaam 18 funksionele variante in ses van die gene, hoofsaaklik in CYP2D6, aan die 
lig gebring. Nuwe variante is in COMT (rs373611092) en SOD2 (rs372173830) geïdentifiseer, waar 
rs373611092 na verwagting die COMT-proteïenfunksie sal “beskadig” (SIFT-telling = 0.015). 
Variante in COMT en DRD2 hou sterk verband met veranderinge in negatiewe PANSS-tellings na 12 
maande se behandeling. Verbande met beter behandelingsuitkomste sluit in COMT rs4633 [P = 
0.0080 (T-allel), UG = -0.17 95% VI (-0.30 tot -0.04)], en DRD2 rs1799732 [P = 0.0004 (-C vs CC), 
UG = -0.19 95% VI (-0.38 tot 0.00)]. COMT-haplotipes (rs2020917-rs737869-rs6269-rs4633-
rs9332377) het ook ’n verbeterde behandelingsuitkoms vir negatiewe simptome getoon. Ongewenste 
behandelingsuitkomste is verbind met COMT rs9332377 [P = 0.0006 (T-allel), UG = 0.25 95% VI 
(0.11 tot 0.39)], en DRD2-variante rs1799732 [P = 0.0004 (-- vs CC), UG = 0.50 95% VI (0.15 tot 
0.86)] en rs1079597 [P = 0.0020 (AA vs AG+GG), UG = 0.93 95% VI (0.34 tot 1.53)].  
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Hierdie studie bevestig dus die unieke variasie in die farmakogenetiese kenmerke van antipsigotika 
by ’n Suid-Afrikaanse FES-kohort, en beklemtoon die waarde van hernude reeksbepaling by Suid-
Afrikaanse individue. Die navorsing toon dat verskeie SNP-verwantskappe vir COMT en DRD2 by 
behandelingsreaksie betrokke is, wat veral negatiewe simptome beïnvloed. Hierdie resultate dien as 
’n platform vir verdere studies oor die farmakogenetika van antipsigotika in Suid-Afrikaanse verband 
ten einde antipsigotikumbehandeling in eiesoortig diverse dog grootliks onbestudeerde populasies te 
help optimaliseer. 
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1 CHAPTER 1: INTRODUCTION 
Psychiatric disorders are a great cause of human suffering and contribute significantly to public 
health and socio-economic burdens. Numerous surveys and assessments, such as the population 
health metric system, disability-adjusted life years (DALYs), have pointed out the significant role 
that mental disorders play worldwide, representing about 7.4% of the global disease burden (Becker 
and Kleinman, 2013). Particularly, the burden of schizophrenia is of great concern as it is ranked one 
of the top ten disease-related disability causes worldwide (Świtaj et al., 2012). This severe disorder is 
further complicated by a heterogeneous aetiology (Purcell et al., 2014). While the prevalence is equal 
in all populations, the burden associated with schizophrenia is much higher in low income countries 
as compared to developed countries, where countries in Europe receive ~30% mental health care 
interventions, but Nigeria receives as low as 2% per year due to limited access of mental health 
resources (Collins et al., 2011; Thornicroft et al., 2012). This highlights the importance of addressing 
the burdens associated with mental health in African populations. Furthermore, populations with 
restricted resources are often faced with poor services for mental health and thus countries that are 
less economically advanced tend to suffer a larger burden in terms of psychiatric diseases when 
compared to other pressing illnesses like diabetes, cancer, cardiovascular and chronic respiratory 
diseases (Marrero et al., 2012; Becker and Kleinman, 2013). For example, in most parts of Africa, 
schizophrenia and related mental diseases have a treatment gap greater than 90%, referring to the 
percentage of patients that do not receive mental care (Saxena et al., 2007; Patel and Prince, 2010). 
In South Africa (SA), a case study performed by Lund and Flisher (2006), revealed that the mental 
health services are disintegrated, lacking adequate resources, and therefore most schizophrenia 
patients’ first hospitalization experiences were unpleasant and distraught (Zubi and Connolly, 2013). 
Psychiatric diseases are largely disregarded, especially in comparison with Human 
Immunodeficiency Virus (HIV) infection, tuberculosis (TB) and malaria (Warnich et al., 2011; 
Asmal et al., 2013). Further distress is brought about by relapse due to treatment discontinuation and 
it has been shown that a 50% relapse rate is observed when those suffering from schizophrenia are 
exposed to criticism or hostility (Emsley et al., 2014). Adverse effects, as well as a poor foundation 
of social support also have negative effects on treatment adherence (Kritzinger et al., 2011). Studies 
that will provide evidence for the biological underpinnings of schizophrenia could therefore help in 
the understanding of the disease, thereby reducing the associated stigma.  
Another vital factor to consider with issues pertaining to mental health in SA is the under-
representation of its diverse populations in previous research due to the limited resources (Wright et 
al., 2011; Burns et al., 2014). According to Statistics SA, the SA population is estimated to comprise 
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of 80.2% Black Africans, 8.8% South African Coloureds (SACs), 8.4% Caucasians and 2.5% Indian 
and Asian individuals as of mid-2014 (South African Department of Health, 2014). The highest 
genetic diversity and largest global admixture is observed for the ancient Khoisan and SAC 
populations, respectively (Tishkoff et al., 2009; Wright et al., 2011). The SAC's interesting admixed 
genetic background makes it a good candidate for population-genetic-based studies due to genetic 
contributions from various parts of the world like Europe, South Asia, Indonesia, Sri Lanka, 
Madagascar, and Western and Southern parts of Africa (Patterson et al., 2010; Alessandrini et al., 
2013). Admixture is also displayed between the Khoisan and ancient Bantu tribes, giving rise to the 
current genetic profiles of the Xhosa population (Tishkoff et al., 2009). The Xhosa population is 
SA’s second largest, comprising about 17.6% of the total population (South African Department of 
Health, 2014).  
By recognizing the complexity in psychiatric disorders such as schizophrenia, and understanding the 
inter-individual differences present in the diverse and under-studied SA populations, better strategies 
can be developed to treat mental disorders more efficiently. It is therefore of great importance to 
identify and understand underlying genetic causes of schizophrenia and treatment outcomes. Studies 
that will investigate treatment response and promise to take unique genetic profiles into account to 
improve treatment outcomes will be quite valuable in addressing the current problems associated with 
treatment. By assessing genetic diversity in relevant genes for SA populations, insight could be 
provided in improving treatment eventually.  
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2 CHAPTER 2: LITERATURE REVIEW 
2.1 Schizophrenia  
2.1.1 Description and Epidemiology 
Schizophrenia is a chronic mental disorder, decreasing life expectancy by 12-15 years (van Os and 
Kapur, 2009). The age of onset usually occurs during the late adolescent or early adulthood years, 
which is the crucial stage presumed to play a role in the development of neuropathology in the brain 
(Gogtay et al., 2011). Schizophrenia has a global life-time prevalence of 0.1-1.7%, depending on 
recovery variation, death and migration rates of suffering individuals (WHO, 2015). A nation-wide 
population based epidemiological study, exploring incidences between 1971-2010, has shown that the 
incidence rate of the early onset of schizophrenia has expanded in recent years and revealed a rate of 
3.17 in 100 000 person years from ages 0-18 (Okkels et al., 2013).  
2.1.2 Diagnosis and Symptoms 
Schizophrenia is diagnosed according to a standardized classification system described by the 
recently updated American-based Diagnostic and Statistical Manual of Mental Disorders version five 
(DSM-5) (Reddy et al., 2014) or by the World Health Organisation’s 10th International Classification 
of Diseases (ICD-10) (van Os and Kapur, 2009). Psychotic symptoms for schizophrenia patients 
overlap with various mental disorders and therefore schizophrenia needs to be critically evaluated due 
to its diverse clinical manifestations and the heterogeneity of the disease (Adam, 2013). 
Clinical symptoms of schizophrenia are comprehensively assessed based on scales such as the 
Positive and Negative Syndrome Scale (PANSS) (Ritsner and Susser, 2009) that comprises of 30 
different psychopathological symptoms, divided into three main groups, namely positive symptoms, 
negative symptoms and general pathological symptoms (Emsley et al., 2003; van Os and Kapur, 
2009). Positive symptoms refer to general psychotic behaviour that include delusions, hallucinations, 
hyperactivity and thought disorders, while negative symptoms arise due to deficits in normal social 
behaviour, such as lack of linguistic skills (alogia), ambition (avolition), pleasure (anhedonia), 
motivation (abulia), as well as affective flattening, attention deficits and asociality (Xu et al., 2013; 
Malhotra, 2014). The remaining symptoms fall under the general psychopathology scale for example 
anxiety, depression, disorientation, etc. and each patient is evaluated through verbal consultation 
based on the PANSS by which the severity is ranked on a scale from 1 – 7, in order of increasing 
severity (Yamamoto et al., 2010).   
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2.1.3 Aetiology of Schizophrenia 
2.1.3.1 Environmental Risk Factors 
Understanding the aetiology of schizophrenia remains challenging due to the complex network of 
interrelated factors playing a role in its pathophysiology that are attributable to both genetic and non-
genetic components (Duan, 2003). Although it is important to investigate genetic factors in 
psychiatric diseases, non-genetic factors are also fundamental to the development of psychiatric 
disorders.  
The stress-diathesis model has proposed environmental triggers to be responsible for the 
susceptibility of schizophrenia. This model suggests that factors like substance abuse (e.g. cannabis 
use), social adversities, traumatic events, infection, paternal age and pregnancy or birth complications 
all play a role in the early onset and risk of schizophrenia (Hadlich et al., 2010; Piper et al., 2012). 
Although these environmental factors are important, Figure 1 highlights that none of these contribute 
as much to the development of schizophrenia as family history, and thus genetics (Sullivan, 2005). 
However, more recent studies have proposed the neurodevelopmental hypothesis to be involved in 
schizophrenia pathogenesis, which reveals that environmental triggers could be activated upon 
genetic predispositions, and epigenetic factors could contribute to defective pre- and postnatal brain 
development (Schmitt et al., 2014).  
 
Figure 1. Environmental risk factors involved in the aetiology of schizophrenia (Sullivan, 2005). CNS: central 
nervous system; depr: depression; Rh: Rhesus. No permission for reuse required from the Public Library of Science 
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2.1.3.2 Genetics of Schizophrenia 
Many studies reveal that genetic factors contribute towards the susceptibility for schizophrenia in 
patients (Vijayan et al., 2007). Evidence for this is supported by adoption and twin studies which 
have shown an estimated heritability as high as 80% (Vijayan et al., 2007; van Os and Kapur, 2009). 
Different models for the genetics of schizophrenia have been proposed, which include the common 
disease-common variant, and common disease-rare variant models, by which the former describes the 
collection of a large number of common single nucleotide polymorphisms (SNPs) obtained from 
genome-wide association studies (GWAS) to contribute to schizophrenia susceptibility, and the latter 
proposes schizophrenia susceptibility to be caused by rare, highly penetrant copy number variants 
(CNVs) evident from their higher frequency associated with disease in genome-wide CNV studies 
(Escudero and Johnstone, 2014). Recent studies have also revealed that the pathogenesis of 
schizophrenia could be linked to risk alleles like de novo mutations which were observed to be 
associated with higher schizophrenia risk due to late paternal age of conception (Kong et al., 2012; 
Veltman and Brunner, 2012; McGrath et al., 2014), thus providing evidence for the role of 
environmental interaction with genetics in the pathogenesis of this disorder. Although schizophrenia 
has manifested itself as a polygenic, multifactorial disorder, various risk alleles are shared between 
schizophrenia and other psychiatric diseases like bipolar disorder, major depressive disorder and 
autism, and these risk alleles are presented in various categories as reported in a recent review (See 
Figure 2) (Rees et al., 2015). Identification of these risk alleles have been facilitated by the 
advancement of sequencing technologies that allow the examination of both common and rare 
variants across multiple genes, which could exhibit significant effects on phenotypes of the disease 
(Purcell et al., 2014). 
 
Figure 2: Risk Alleles associated with schizophrenia (Rees et al., 2015). MAF: minor allele frequency; OR: odds 
ratio; CNV: copy number variation; SNV: single nucleotide variant; indel: insertion/deletion; ARC: activity-
regulated cytoskeleton-associated protein; NMDAR: N-methyl-D-aspartate receptor; FMRP: fragile X mental 
retardation protein; BD: bipolar disorder; MDD: major depressive disorder; ASD: autism spectrum disorder. 
Reprinted with permission from Elsevier 
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2.1.4 Neurochemical Influences on Schizophrenia 
Although many factors are speculated to be involved in the pathogenesis of schizophrenia, the most 
well-documented are the defective neuro-circuitries involving various modulatory neurotransmitters. 
Chemical imbalances in neurotransmitter systems in the prefrontal cortex of the brain have been 
hypothesized to be responsible for the pathophysiology of schizophrenia (Orhan et al., 2014). The 
dopamine hypothesis describes the dysregulation of dopamine neurotransmission resulting in the 
psychosis of schizophrenia. It is for this reason that antipsychotic drugs are designed to target this 
system to relieve psychotic symptoms by dopamine receptor antagonism (Cookson, 2013). Currently, 
this hypothesis is still valid as imbalances in dopamine systems have shown to alter cognitive 
functioning, where positive symptoms are correlated with dopamine hyperactivity and negative 
symptoms are displayed by dopamine hypo-activity in the brain (Guillin et al., 2007).  
The serotonin hypothesis has also been linked to schizophrenia by the hyperactivity of serotonin, 
leading to psychotic symptoms and also affecting dopamine regulation as well as other 
neurotransmitter systems (Eggers, 2013). Animal studies revealed that disruptive serotonin receptors 
result in psychosis and depression (Richardson-Jones et al., 2011) and dysregulation of serotonin 
systems in patients is linked to the negative symptomology of schizophrenia (Strauss et al., 2013). 
Dopamine neurons play a role in the mechanism of drug treatment by releasing serotonin in the 
midbrain, preventing excessive serotonergic activity in certain brain regions. The interactions 
between dopamine and serotonin are important and homeostasis is required to prevent psychoses 
(Seutin, 2005). Therefore, dopamine and serotonergic systems seem to be intertwined and disruptions 
of the one system might affect the other, which may affect the other neurotransmitter circuitries that 
contribute to the complexity of schizophrenia pathophysiology (Vyas et al., 2013).  
A number of studies have also revealed that oxidative stress, causing cell toxicity and damage as a 
result of the build-up of free radicals as by-products, may be implicated in the aetiology of 
schizophrenia (Ng et al., 2008; Bitanihirwe and Woo, 2011; Yao and Reddy, 2011). The brain is 
vulnerable to oxidative stress due to its high oxygen usage in various metabolic processes like lipid 
metabolism, neurotransmitter pathways and various enzymatic reactions (Bošković et al., 2011). 
Superoxide dismutase 2 (SOD2) is an important antioxidant responsible for preventing the damage 
caused by these free radicals, called reactive oxygen species (ROS). ROS occurs naturally as a by-
product of biochemical reactions, causing cell and neural toxicity due to oxidative stress. As a result 
of the role that this protein plays, aberrant SOD2 enzymes can greatly influence neurodevelopment 
and therefore it is important to elucidate SOD2 activity for better management of psychotic 
symptoms (Chowdhury et al., 2011). The importance of oxidative stress is illustrated in Figure 3, 
which highlights the involvement of many factors in schizophrenia pathogenesis. These aspects 
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include both environmental and genetic influences, involving various biological processes like 
inflammation, neuronal damage, epigenetic factors, mitochondrial dysfunction, N-methyl-D-aspartate 
(NMDA) or glutamate receptor hypo-activity, etc. (Bitanihirwe and Woo, 2011). These molecules, 
involving aberrant neurotransmission systems, are all linked to the mechanism of action of 
antipsychotic drugs. Comprehensive findings of neurotransmission networks will therefore improve 
our understanding of schizophrenia treatment and enable us to develop effective treatment schemes. 
 
Figure 3: Interrelated factors involved in the oxidative stress in schizophrenia aetiology (Bitanihirwe and Woo, 
2011). NMDA: N-methyl-D-aspartate; PV: parvalbumin. Reprinted with permission from Elsevier 
2.1.5 Treatment 
Antipsychotic medication is currently used to treat psychosis in schizophrenia and has been the most 
effective method of treatment for the disorder in the past fifty years (Peluso et al., 2012). 
Antipsychotic medications have significantly improved the treatment of schizophrenia and have 
shown to be more effective than placebo drugs by decreasing relapse rates and readmissions of 
patients, as well as improving the quality of patients’ lives (Leucht et al., 2012). These drugs fall into 
two categories, the typical or first generation antipsychotics (FGAs) and the more recent, atypical or 
second generation antipsychotics (SGAs), which display similar efficacies and are therefore both still 
currently used to treat symptoms of schizophrenia (Hartling et al., 2012). Neurotransmission systems 
are the main sites of antipsychotic drug therapy as these drugs are designed to act as antagonists by 
targeting and blocking receptors from binding to neurotransmitters that regulate brain functionality 
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(Lohoff and Ferraro, 2010). FGAs generally target dopamine receptors as they have a high affinity 
for these receptors, ultimately alleviating positive symptoms (Lafuente et al., 2007). Unfortunately, 
these drugs are not effective in treating other dimensions of schizophrenia symptoms and often cause 
critical involuntary movements like tardive dyskinesia (TD) and other extra-pyramidal side effects 
(EPS), and are also associated with a poor quality of life and increased burdens of morbidity and 
mortality (Correll et al., 2004; Lieberman et al., 2005). FGAs include drugs like chlorpromazine, 
haloperidol, perphenazine and flupenthixol, which have been used for the past five decades and 
demonstrate effective treatment of schizophrenia (Shen et al., 2012). SGAs like clozapine, 
risperidone, olanzapine, ziprasidone, and aripiprazole show less undesirable EPS, but cause acute 
weight gain and other unwanted side effects that include changes in lipid and glucose metabolism, 
which in turn can lead to the development of cardiovascular diseases and diabetes mellitus (Kusumi 
et al., 2011). These atypical drugs not only target dopamine receptors, but also have the ability to 
target serotonin receptors, distinguishing them from FGAs, and are generally the recommended drugs 
prescribed to patients as it produces minimal EPS (Meltzer, 2013). However, SGAs are relatively 
expensive in comparison to FGAs. For this reason typical drugs are often prescribed in circumstances 
where medical resources are limited (Bukhsh et al., 2014) and are thus used in developing world 
settings like SA. Consequently, much attention is needed to try and comprehend treatment efficacy in 
the long-term as both FGAs and SGAs are accompanied by distressing side effects and treatment 
failures (Lieberman et al., 2005; Lencz and Malhotra, 2009). However, optimizing low cost drugs 
would be beneficial to resource limited settings in the developing world.  
2.2 Antipsychotic Pharmacogenetics 
2.2.1 Pharmacogenetics of Schizophrenia 
Pharmacogenetics is a term ascribed to the inherited genetic variation within individuals or across 
populations, causing changes in the regulation of gene networks, which influences drug pathways and 
causes individuals to respond differently to therapeutic treatments (Roden et al., 2011). Therefore it is 
important to characterize the genetic differences observed between individuals and populations. 
Recent research efforts have greatly contributed to the growing field of pharmacogenetics and the 
establishment of the International HapMap consortium and 1000 Genomes Project has played an 
important role in indexing most of the common genetic variation present in the human genome 
(Deloukas and Bentley, 2004). These projects characterize human variation in global populations, 
allowing researchers to use these resources to facilitate the use of genetic approaches that could 
identify networks of polymorphisms from different genes involved in treatment outcomes of patients 
suffering from various disorders.  
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The role of genetics in antipsychotic treatment has been validated by a number of sibling and twin 
studies, which have demonstrated that improved clozapine and olanzapine outcomes are in strong 
concordance with monozygotic twins (Reynolds, 2012). As antipsychotic medications do not always 
exhibit optimal efficacy, pharmacogenetic studies are likely to play an important role in improving 
these treatments. Not only do antipsychotics fail to reduce schizophrenia symptoms in about 50% of 
patients (Miyamoto et al., 2005; Lohoff and Ferraro, 2010), but they also cause undesirable side 
effects or adverse drug reactions (ADRs). FGAs have a narrow therapeutic range since 60% of 
dopamine receptor blockage is needed for a therapeutic response to occur, but a greater than 80% 
blockage can lead to the development of ADRs (Lohoff and Ferraro, 2010). It is important to 
therefore understand the pharmacogenetics of antipsychotic drugs in order to try and improve 
treatment outcomes by preventing drug toxicity and inefficacy. Therefore, pharmacogenetic studies 
are urged to identify genetic variants that can help to optimize these important treatments that are 
plagued by non-optimal outcomes.  
Studies that incorporate pharmacogenetics may identify potential genetic predictors of the drug 
response (Malhotra et al., 2004). The utility of this approach is highlighted by studies such as those 
performed by Arranz et al. (2000), which reported a significant association of six variants across 
multiple genes with clozapine response, showing a predictive value as high as 77% (Kohlrausch, 
2013). Numerous association studies are currently being performed to determine pharmacogenetic 
traits by comparing responders to non-responders or patients experiencing ADRs, in clinical trials of 
drugs and other studies (Weiss et al., 2001). However, these approaches are hampered by a number 
of heterogeneous factors that can influence the statistical outcome of the study, including the 
multifactorial nature of each individual’s response to medication.  
Multifactorial components influencing phenotypic response can be difficult to measure and is a huge 
drawback in understanding the treatment of schizophrenia. Important parameters that should be 
considered include: i) the type of antipsychotic medication given to each patient, ii) response 
characterization, iii) the duration of treatment, iv) the population sample size, and v) the ethnic 
background of the patient (Cichon et al., 2000), as well as inter-individual differences affected by 
age, gender and lifestyle. Another important parameter is the careful clinical characterization of 
patients that will improve the ability to detect variants in association with treatment outcome. For 
instance, the course of illness is quite crucial in detecting a statistical outcome as it has been shown 
that patients experiencing their first episode of psychosis have a much higher response rate compared 
to chronically ill patients (Robinson et al., 1999; Chiliza et al., 2015). The importance of considering 
mental illnesses at early phases can therefore be quite useful to pharmacogenetic research as it avoids 
issues like concomitant treatment and adherence.  
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Treatment adherence is another issue which affects pharmacogenetics studies, as patients suffering 
from mental diseases are inclined to experience non-adherence with adherence rates for 
schizophrenia patients reported to be between 20-72% (Julius et al., 2009).  This can cause 
symptomatic relapse in a study focusing on adverse reactions, but the effect of this power has not 
been enumerated yet (Malhotra et al., 2012). Therefore, improving the adherence rates of medication 
can allow for small sample sizes to be sufficient, increasing the statistical power. The adherence rates 
of cohorts can be more accurately measured if the patients receive their medication via injection, thus 
excluding the inconsistencies in treatment adherence. The use of first episode patients in a 
phamacogenetic study is therefore quite beneficial as it addresses many of the issues associated with 
clinical heterogeneity. Table 1 briefly summarizes some of the challenges that need to be evaluated 
for antipsychotic treatment response in patients.  
Table 1: Evaluation of challenges concerned with treatment outcome in pharmacogenetics research of schizophrenia 
patients (Arranz et al., 2011). Reprinted with permission from Elsevier 
Characteristic Considerations 
Patient characteristics 
Diagnosis Differential diagnosis during an initial episode of psychosis may not be clear. 
Schizophrenia studies may be confounded by inclusion of diverse disorders (e.g. 
affective or drug-induced psychoses) 
Illness course Treatment response will be different for patients with treatment-resistant schizophrenia or 
a first-episode psychosis 
Co-morbidities Drug abuse and depression are common and influence treatment outcome 
Treatment episode characteristics 
Antipsychotic drug prescribed Among different antipsychotics, varying receptor affinities and profiles may result in 
different gene variants influencing treatment outcome 
Treatment adherence Non-adherence to antipsychotic medication is common (usual) 
Concomitant medication Concomitant mood stabilizers or antidepressants are common. Dove-tailing 
antipsychotics at switching may also complicate response assessments 
Treatment duration Most improvement in positive symptoms occurs in the initial weeks; however, 
progressive improvement may occur beyond a year of treatment (e.g. with clozapine) 
Outcome phenotype characteristics 
Assessment of efficacy Antipsychotic efficacy is a complex outcome phenotype. Whilst most studies use 
standardized outcome measures such as the Positive and Negative Syndrome Scale 
(PANSS), the association of genetic variants with a multidimensional, composite 
outcome scale is challenging. ‘Real life outcomes’ (e.g. level of functioning) may have 
more relevance for pharmacogenetic tests used in clinical care 
Assessment of adverse effects Some adverse effects may be very robustly measured (e.g. weight gain or lipid levels), 
while others are more subjective (e.g. tardive dyskinesia) 
Confounding factors Confounding factors may influence outcome (e.g. risk of tardive dyskinesia is increased 
in female patients, in individuals of African Caribbean origin and with age over 50 years) 
Baseline state Baseline state influences the degree of symptom improvement and adverse effects (e.g. 
patients with low body mass index have the highest risk of antipsychotic-induced weight 
gain) 
 
All factors mentioned previously play a huge role in the understanding of the antipsychotic treatment 
response mechanism. Hence, it is important to develop a study design that will be useful in a clinical 
setting, allowing patients to be treated more effectively by tailoring their medication according to 
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their genetic profiles. A number of candidate genes have been proposed to influence pharmacogenetic 
traits with regards to antipsychotic exposure. These genetic interactions occur on two dimensions of 
antipsychotic drug processes, namely pharmacodynamics and pharmacokinetics. Pharmacodynamic 
processes directly affect neurotransmission networks by targeting receptor sites, altering levels of 
these neurotransmitters in the brain. This phenomenon explains how drugs interact with these 
receptors and with other drugs that can create agonistic or antagonistic effects. Pharmacokinetics 
alternatively focuses on the metabolism of the drug itself and its metabolites and all pathways 
involved in its mechanism of action (Spina and de Leon, 2007).  
2.2.2 Pharmacodynamics of Antipsychotics 
Dopamine and serotonin neurotransmitter receptors are the prime targets for antipsychotic drugs, as 
imbalances in the levels of their relative substrates have been shown to be causal elements of 
schizophrenia and other psychotic symptoms in psychiatric diseases (Zhang et al., 2010). Various 
enzymes involved in these neurobiological pathways play an important role in the regulation of these 
neurotransmitters. Present-day antipsychotic medication operates on a broader scope by targeting 
other neurotransmitters hypothesized to be associated with negative symptoms of schizophrenia and 
include epinephrine/norepinephrine, histamine and other acetylcholines (Arranz and de Leon, 2007). 
However, the roles of dopamine and serotonin in the mechanism of antipsychotic drugs are 
accentuated since both dopamine (D2) and serotonin (HTR2A) receptors have been shown to regulate 
prefrontal activity in the cortex and antipsychotic treatment response in schizophrenia patients, 
credited to the genetic variation present in the genes coding for these receptors (Blasi et al., 2015).  
2.2.2.1 Dopamine 
Dopamine dysregulation has been implicated in the pathophysiology of schizophrenia and its link to 
symptom severity is explained by the dopamine hypothesis, stating that psychosis occurs due to 
dopamine imbalances in the brain (Howes and Kapur, 2009).  The first drugs developed were 
therefore aimed at targeting dopaminergic receptors, hence FGAs’ favourable affinity for dopamine 
receptors (Miyamoto et al., 2005; Arranz and de Leon, 2007). Dopamine receptors are classed into 
five subtypes, D1-D5, but most pharmacogenetic studies have focused on receptor types D2, D3 and 
D4, mainly because haloperidol, a FGA, shows a stronger affinity for these receptors (Miyamoto et 
al., 2005; Arranz and de Leon, 2007; Zhang and Malhotra, 2011).  
The dopamine receptor D2 gene (DRD2) is involved in controlling motor activity, neuro-endocrine 
functioning and cognition (Duan, 2003).  Several genetic variants that alter regulation and expression 
levels of DRD2 have been described. The deletion allele of rs1799732, located in the 5’ untranslated 
region of the gene, has been associated with decreased promoter activity, resulting in a decline in 
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expression levels of the downstream coding regions (Arinami et al., 1997; Lafuente et al., 2007; Mi 
et al., 2011). Patients carrying this allele display poorer response to treatment compared to patients 
with the Ins/Ins (CC) genotype (Zhang et al., 2010; Zhang and Malhotra, 2011). The presence of the 
deleterious allele of this SNP was also reported to be associated with escalating positive symptoms in 
schizophrenia patients (Sáiz et al., 2010). The rs1800497 and rs1079597 SNPs in DRD2 are also 
commonly studied polymorphisms that have been reported to result in reduced receptor density in the 
striatum, indicating increased levels of dopamine in this region, and patients carrying these variants 
are more likely to respond better to treatment (Vijayan et al., 2007). Patients homozygous for the C 
or A2 allele of rs1800497 display a significant decrease in PANSS scores after treatment (Mi et al., 
2011) whereas for rs1079597, the homozygous G (B1) genotype have shown to be associated with 
severe hallucinations (Vijayan et al., 2007; Zhang and Malhotra, 2011). 
D3 receptors, encoded by the DRD3 gene, are located in the limbic regions of the brain (Schwartz et 
al., 2000), thus controlling impulse and basic emotions and are preferred targets for antipsychotic 
drugs compared to D2 receptors (Graff-Guerrero et al., 2009). A non-synonymous variant, rs6280 
(Ser9Gly), occurring within this gene, has been investigated in a meta-analysis study and reported the 
Ser allele to be associated with non-responsiveness to the atypical antipsychotic drug, clozapine 
(Jönsson et al., 2003). Similarly, further investigation from a larger meta-analysis performed by 
Hwang et al. (2010) revealed a negative trend for the Ser allele to poor response of clozapine 
treatment. This study showed that this SNP could be a potential candidate involved in treatment 
response, but highlighted that improved study designs need to be implemented to eliminate 
inconsistent findings.  
Catechol-O-methyltransferase (COMT) is a catabolic enzyme responsible for the degradation and 
removal of dopamine in the prefrontal cortex (Chen et al., 2004). Variation in the COMT gene have 
been implicated in dopamine receptor density, thereby regulating dopaminergic systems (Williams et 
al., 2007). COMT variation have been associated with improved cognition with clozapine treatment 
and negative symptoms correlated to prefrontal dopaminergic activity (Bosia et al., 2014). A study 
performed by Wright et al. (2012) highlights the important role of the COMT P2 promoter region 
within a SA Xhosa population and negative symptom severity, indicating unique haplotype 
associations for African populations as they display the highest level of genetic diversity. Genes 
involved in dopamine neurotransmission are therefore good candidates for investigating antipsychotic 
treatment outcomes due to the roles of the antipsychotic medication in these networks. 
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Serotonin 2A receptors (HTR2A) are important in maintaining the levels of serotonin and are the 
principal targets for SGAs, thereby lowering the likelihood of developing ADRs since HTR2A are 
the favoured targets over dopamine receptors (Casey, 2004). These serotonin receptors are commonly 
dispersed throughout the cortex of the brain and are more effective in alleviating cognitive defects on 
which drugs like clozapine, risperidone and olanzapine bind with a high affinity (Mamo et al., 2004; 
Meltzer, 2013).  
A well-studied synonymous variant, rs6313 (T102C) in HTR2A, which is in complete linkage 
disequilibrium (LD) with a functional variant, rs6311 (A-1438G) in the promoter region in 
Europeans, has shown to be associated with response to clozapine and risperidone with contradictory 
results. Reduced promoter activity has been observed for the G allele of the promoter polymorphism, 
indicating less 2A receptors present in the brain, thus altering serotonergic-dopaminergic pathways 
through antipsychotic mediation of serotonin/dopamine binding affinities (Arranz and de Leon, 2007; 
Zhang and Malhotra, 2011). However, many studies could not replicate significant findings for 
rs6313, for both FGA and SGA response, suggesting it is a weak candidate (Masellis et al., 1998; 
Malhotra, 2014). Various polymorphisms in serotonin genes have been shown to significantly predict 
treatment response, but findings could not be replicated in later studies (Arranz et al., 2000; Zhang 
and Malhotra, 2013). 
2.2.2.3 Other Neurotransmitters 
Cognitive abilities are largely affected by several neurotransmitters that include glutermatergic, 
adrenergic, histamine and muscarinic receptors, to which atypical antipsychotics have a great binding 
affinity (Chiu et al., 2003; Bishop et al., 2015). Even though adrenergic and histamine receptors are 
good targets for SGAs, no genetic evidence is available to explain the association to treatment 
response.  Likewise with muscarinic receptors, insignificant associations to clozapine efficacy were 
detected. However, more research has to be carried out to fully understand the link between these 
neurotransmitters and antipsychotic efficacy (Arranz and de Leon, 2007).  
2.2.3 Pharmacokinetics of Antipsychotics 
The cytochrome P450 (CYP) system is the chief pharmacokinetic site of most antipsychotic drugs 
(Nelson et al., 1996; Spina et al., 2003). Two distinct metabolic reactions occur with regards to 
antipsychotic medication, namely Phase I and Phase II reactions that are involved in the oxidation of 
antipsychotic metabolism and the inactivation of its metabolites, respectively, where CYP enzymes 
are primarily involved in Phase I reactions (Roth and Alici, 2014). CYP enzymes are highly 
polymorphic and have built up several mutations that give rise to variant alleles, resulting in 
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differential gene expression and activity (Spina and de Leon, 2007). These enzymes in conjunction 
with external factors (e.g. smoking, diet, alcohol and substance abuse), influence antipsychotic 
pharmacokinetics (Arranz et al., 2011). Genetic variations occurring within genes encoding these 
enzymes result in patients exhibiting disparate phenotypes, such as poor metabolizers (PMs) who 
lack functional enzymes due to defective or deleted genes, intermediate metabolizers (IMs) that carry 
one functional and one defective allele, extensive metabolizers (EMs) that carry two functional 
copies of the gene, and ultra-rapid metabolizers (UMs) that carry more than two active copies of the 
gene or exhibit increased expression alleles (Spina and de Leon, 2014).  
2.2.3.1 CYP1A2 
The CYP1A2 enzyme plays a significant role in the metabolism of many FGAs and SGAs, 
specifically clozapine and olanzapine (Tiwari et al., 2005). This enzyme is impeded by caffeine, 
causing elevated plasma levels of antipsychotic metabolites and can also decrease antipsychotic 
potency when taken with concomitant drugs that can in turn lead to the development of ADRs (Spina 
and de Leon, 2007; Arranz et al., 2011). The activity of CYP1A2 is highly influenced by smoking, 
showing increased metabolism with CYP1A2*1C and CYP1A2*1D genetic variants (Pavanello et al., 
2005), and these patients require dosage adjustments for the antipsychotics they are treated with. A 
recent study reported that the CYP1A2*1F/*1F genotype was associated with reduced olanzapine 
serum concentration in the absence of inducers, indicating a poor treatment outcome (Laika et al., 
2010), and included associations with TD development (Fu et al., 2006). However, some studies 
revealed no association with CYP1A2 variants and clinical efficacy of olanzapine (Ravyn et al., 
2013). Differences in CYP1A2 frequency variation highlight the importance of investigating these 
variants in different populations to determine the influence on antipsychotic outcomes (Szalai et al., 
2014). 
2.2.3.2 CYP2D6 
The CYP2D6 gene is highly polymorphic, resulting in various phenotypic expressions that occur as a 
result of diverse variations such as duplications and deletions. Patients with reduced and normal 
CYP2D6 activity are classified as PMs and EMs respectively, and when multiple copies of the gene 
are present they are classed as UMs. Interestingly, not all patients with additional copies of CYP2D6 
are described as UMs because not all copies of the duplicated gene are functional (Ravyn et al., 
2013). About 7-10% of Caucasians and 1-2% of Asians are classified as PMs, and require minimal 
antipsychotic doses for therapeutic responses to occur. PMs may also display ADRs due to high 
plasma levels of antipsychotic drugs (Arranz and de Leon, 2007; Gaedigk and Coetsee, 2008). Figure 
4 briefly describes the genetic mechanisms associated with CYP2D6 metabolic status and its 
resulting therapeutic outcome. Ravyn et al. (2013) have also reported a number of studies to show a 
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significant association of CYP2D6 PM status with increased plasma concentrations of the typical 
drug, haloperidol, and its slow clearance as compared to EMs, concluding that the dose be reduced to 
50% in these cases. They report similar findings for most FGAs but inconclusive findings when 
compared to SGAs, where no difference in plasma levels between the various metabolizer 
phenotypes were observed. Recently, studies have linked CYP2D6 PM phenotype with an increased 
risk of Parkinson’s disease (Persson and Ingelman-Sundberg, 2014). However, inferring phenotypic 
information from CYP2D6 genotypes is difficult due to the vast number of variants within this gene, 
by which many have not been characterized, and no set method is available for genotype-phenotype 
prediction, thus leading to the discrepant results reported. Wright et al. (2010) devised a useful 
genotyping strategy for the SA Xhosa population and demonstrated the unique genetic profiles 
present within this population, including novel variants detected. The importance of this gene in 
pharmacogenetic research is quite valuable because of its polymorphic nature, producing inter-
individual differences amongst patients in drug response dosages, ultimately affecting drug efficacy 
(Xu et al., 2013).  
 
Figure 4. Genetic mechanisms for CYP450 metabolic phenotypes and pharmacokinetic implications (Ravyn et al., 
2013). Reprinted with permission from Elsevier 
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2.2.4 Antipsychotic Adverse Drug Reactions 
Although inter-individual differences exist between antipsychotic treatment response profiles in 
patients, it is important to also consider the differences that occur with the various side effects. ADRs 
are a huge burden in psychiatric diseases, as they cause severe reactions that in many cases are 
permanent, leading to high rates of treatment failures and increase the socio-economic burdens placed 
on patients. The evolution of SGAs has reduced the burden of threatening EPS caused by FGAs, 
however they are still accompanied with ADRs (Arranz et al., 2011).  
TD, a critical involuntary and permanent movement disorder, is amongst one of the most concerning 
ADRs caused by antipsychotic drugs and about 25% of schizophrenia patients on long-term treatment 
with typical antipsychotics develop TD. The genetics underlying its mechanism is of great value in 
pharmacogenetics research as this prior genetic knowledge can assist in treating patients more 
effectively (Zai et al., 2010). Oxidative stress resulting in neuro-degeneration is an important aspect 
speculated to be responsible for the pathology of TD. The SOD2 gene was investigated in a meta-
analysis study by (Bakker et al., 2008) and a significant association with TD was discovered, 
including an association between the rs4880 SNP and TD severity in a study by Kang et al. (2008). In 
a different study, this SNP had relevance to movement disorders because patients that were carriers 
of the Ala variant developed TD (Chowdhury et al., 2011).   
Other ADRs commonly reported in pharmacogenetic studies include weight gain and metabolic 
syndrome, which have been shown to be associated with most modern antipsychotics, like clozapine 
and olanzapine, indicating a risk twice as high in schizophrenia patients, and thus causing many 
health issues that include type 2 diabetes mellitus, coronary heart disease and hypertension 
(Panariello et al., 2010). Agranulocytosis is a very rare ADR, but quite detrimental and strongly 
associated with the use of clozapine (Arranz et al., 2011). 
Although a considerable number of studies have been performed to understand the antipsychotic 
pharmacogenetics of schizophrenia, many discrepancies still remain due to the complex mechanism 
of the disease and its treatment response profiles.  Many findings have not been replicated, probably 
caused by factors like study design, sample size and ethnicity that differed between studies. However, 
further replicative studies are warranted to elucidate the complexity of treating this disorder. Since 
antipsychotic response phenotype shows inter-individual variability and prediction of these responses 
is difficult, pharmacogenetics could play an important role in identifying genetic factors, which could 
positively influence treatment outcome in psychiatric disorders (Zhang et al., 2010; Zhang and 
Malhotra, 2011).  
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2.3 Gene Selection and Cohort Used for This Study 
The candidate pharmacogenes selected in this study have been shown to influence treatment outcome 
based on genetic variants present within these genes. The pathways involved in these genes have 
been implicated in neurotransmission and drug mechanism in a number of studies. These genes 
encode important receptors and enzymes involved in dopamine and serotonin pathways, as well as 
CYP enzymes like CYP1A2 and CYP2D6, primarily involved in antipsychotic metabolism. SOD2 
also plays a pivotal role in counteracting the toxicity caused by ROS, preventing neural damage 
caused by oxidative stress. The following candidate genes were therefore selected for this study due 
to their implication with antipsychotic pharmacogenetics of schizophrenia: COMT, CYP1A2, 
CYP2D6, DRD2, DRD3, HTR2A and SOD2. Although this study focused on a number of important 
pharmacogenes for antipsychotics, it is important to note that the study did not include a 
comprehensive list of all pharmacogenes that are important for antipsychotics. 
This study utilized a well-defined first episode schizophrenia (FES) cohort that has been under-
represented in pharmacogenetic research. They comprise of SA Coloured (SAC), Caucasian and 
Xhosa individuals, treated on their first psychotic account without or with limited exposure to 
previous intervening medication. The value of this cohort is emphasized by the elimination of 
confounding factors such as inconsistencies in diagnosis and antipsychotic treatment, which could 
interfere with the phenotypic assessment (Chiliza et al., 2014). This ensures an unbiased study that 
will enable us to better understand the complexity of genetic interaction and treatment outcome, 
further relieving disease burden presented on a multifaceted scale. The SAC, Caucasian and Xhosa 
populations also hold distinctive and unique genetic variation profiles, which could have important 
implementation in a clinical-diagnostic setting. Furthermore, this study builds on previous work 
performed in our research group to investigate the effects of genetic variation presented in the under-
represented SA populations on treatment outcomes. To our knowledge, this is the first study to 
investigate these genes in a FES SA cohort.  
2.3.1 Research Problem and Rationale 
Optimizing antipsychotic treatment of schizophrenia can be challenging due to the complexity of the 
disorder and treatment outcome. Research efforts are constantly investigating ways to enhance drug 
efficacy and decrease toxicity and relapse rates, which remains a huge burden. The criteria for the 
selection of genes were based on the most frequently occurring variants found in literature, which 
were most consistently reported to be involved in the pharmacogenetics of schizophrenia. By 
investigating these genes, the relationship between genetic variants and treatment outcome can be 
established, leading to an improved understanding of treatment outcomes and ultimately facilitating 
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treatment modifications to decrease toxic properties and improve the efficacy of treatment. This will 
aid in allowing for tailored treatment to be acquired in a clinical setting.   
2.3.1.1 Aim  
This study aims to determine if polymorphisms in candidate pharmacogenes are associated with 
antipsychotic treatment outcomes in a South African first episode schizophrenia cohort.  
2.3.1.2 Objectives 
 Identify candidate pharmacogenes implicated in pharmacogenetics of schizophrenia from the 
literature. 
 Perform bioinformatic analyses to identify and characterize the genetic variants in the 
prioritized candidate pharmacogenes using previously generated exome sequencing data. 
 Prioritize variants based on the literature and in silico analyses of exome data. 
 Design genotyping assays and genotype prioritized polymorphisms in COMT, CYP1A2, 
CYP2D6, DRD2, DRD3 and SOD2 in a South African first episode schizophrenia cohort. 
 Determine the allele, genotype and haplotype frequencies of all prioritized variants. 
 Compare minor allele frequencies of variants in our cohort with populations from the 1000 
Genomes Project and the Human CYP Allele Nomenclature Databases. 
 Perform association analyses to establish if there are genetic polymorphisms that are 
associated with antipsychotic treatment outcome. 
2.3.1.3 Study Design 
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3 CHAPTER 3: MATERIALS AND METHODS 
3.1 Patient Samples 
The patient cohort was selected from a larger cohort obtained for a non-comparative study (Chiliza et 
al., 2014) that investigated the treatment response profiles to the conventional antipsychotic, 
flupenthixol decanoate in FES patients, diagnosed using the DSM-IV (American Psychiatric 
Association, 2000). The drug was administered subsequent to a 7-day wash-out period, by treating 
each patient with flexible doses of flupenthixol decanoate injections. The initial prescribed dose 
included 10 mg of flupenthixol decanoate every 2 weeks, with 10 mg increments every 6 weeks 
allowed, not exceeding 30 mg every 2 weeks. Concomitant psychotropic treatment was allowed if 
necessary, which included benzodiazepines, antidepressants or anticholinergics. Other antipsychotics, 
mood stabilizers or psychostimulants were not permitted (Chiliza et al., 2015). From the 207 patients 
that were eligible in the study, 126 resided in and around Cape Town and for 104 of these, genomic 
DNA (gDNA) samples were available. However, since only unrelated individuals were considered in 
this study, one patient was excluded leaving a total of 103 patients for inclusion in this study. These 
individuals’ identity was anonymized for the purpose of this study and the patients were recruited 
from Stikland Hospital in the Western Cape, where they have been clinically evaluated for at least 12 
months. Extensive clinical and demographic data were collected for all the patients (Table 2) at 
baseline, week 2, week 4, week 6 and every 3 months thereafter. The data included PANSS scores 
assessed accurately by medical doctors trained to use assessment instrumentation and underwent 
inter-rater reliability testing of a >75% for all scales prior to the study. These PANSS scores were 
used to measure treatment response in this study. gDNA was previously extracted from whole blood 
using the Miller et al. (1988) protocol. Genotype data for ancestry informative markers (AIMs) were 
also available for the cohort (Daya et al., 2013; Drögemöller et al., 2013). Prior to the study, written 
or verbal informed consent was obtained from the patients themselves or their caregivers. Ethical 
approval was obtained from the Health Research Ethics Committee (HREC), Faculty of Health 
Sciences, Stellenbosch University, in terms of the Health Act No 61.2003 (ethics review numbers for 
clinical and genetic aspects: N06/08/148 and 1907/005, respectively).  
Table 2. Patient demographic data (Chiliza et al., 2014; Drögemöller et al., 2014a). Reprinted with permission from 
Future Medicine 
Patient demographic descriptor  Count, n (%)  
Mean age (years)  24 ± 7  
Gender  
Male  76 (74)  
Female  27 (26)  
Ethnicity  
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African descent (Xhosa) 13 (13)  
Mixed ancestry (SAC) 82 (80)  
European descent (Caucasian) 8 (8)  
Highest level of education  
Elementary school  7 (7)  
Secondary school  65 (63)  
Matriculation  21 (20)  
Tertiary education  8 (8)  
Technical college  2 (2)  
Marital status  
Single  87 (84)  
Married  8 (8)  
Divorced  5 (5)  
Widowed  2 (2)  
Cohabiting  1 (1)  
Urban vs rural living  
Urban  101 (98)  
Rural  2 (2)  
Previous antipsychotic medication  
No  57 (55)  
Yes  46 (45)  
Family history of psychosis  
None  41 (41)  
Schizophrenia  38 (38)  
Bipolar  1 (1)  
Depression  5 (5)  
Substance abuse  7 (7)  
Other  9 (9) 
 
3.2 Prioritization of Variants  
Genes selected in this study (COMT, CYP1A2, CYP2D6, DRD2, DRD3, HTR2A and SOD2) have 
been chosen based on pathways implicated in the pharmacogenetics of schizophrenia, i.e. dopamine 
and serotonin neurotransmission, the cytochrome P450 system and oxidative stress (Zhang et al., 
2011). A literature search was conducted on Google Scholar (https://scholar.google.co.za/) using the 
keywords “schizophrenia pharmacogenetics” and “antipsychotic pharmacogenetics” in the search tool 
(accessed 16 January 2012).  The search criteria was filtered according to a publication date of at 
least five years prior to the study and only “full-text” articles were considered, available via the 
Stellenbosch University Library and Information Service portal 
(http://library.sun.ac.za/English/Pages/default.aspx) (accessed 16 January 2012). References of 
identified articles were examined for additional relevant citations. The remaining articles were mined 
to identify the most commonly cited candidate genes implicated in the pharmacogenetics of 
schizophrenia and the chosen variants have all demonstrated evidence for playing a role in the 
dopamine, serotonin and drug metabolism pathways, which included intronic, missense, synonymous 
and frameshift mutations.  
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The candidate genes selected were further investigated for novel and known functional variants 
within previously generated exome data for eleven of the FES patients from SAC ethnicity, of which 
five were responders and six non-responders to antipsychotic medication. These data were available 
in variant call format (vcf) and were generated as described by Drogemöller et al. (2014b). Data for 
the COMT, CYP1A2, CYP2D6, DRD2, DRD3, HTR2A and SOD2 genes were extracted from the vcf 
file using the awk utility (awk ‘$21 ~ /gene_name/’ vcf_file_name.txt > gene_name.txt). These data 
were subsequently submitted to SeattleSeq Annotation 141 (Ng et al., 2010) using default settings in 
order to annotate variants within the candidate pharmacogenes. Variants were classified as functional 
if they were predicted in silico to affect gene products (loss-of-function, missense or splice-site 
mutations). Variants predicted by SeattleSeq Annotation 141 to affect the gene function were further 
analyzed by means of the Sorting Intolerant from tolerant (SIFT) (Kumar et al., 2009) and 
Polymorphism Phenotyping (PolyPhen-2) (Adzhubei et al., 2010) algorithms and the severity of the 
variant was considered likely to affect the protein function if the variant was classified as “damaging” 
by at least one of the algorithms. Novel variants identified were submitted to the National Center for 
Biotechnology Information Single Nucleotide Polymorphism database (NCBI dbSNP) 
(http://www.ncbi.nlm.nih.gov/snp/) to obtain rs IDs for these variants. Relevant genotyping assays 
were developed for novel functional variants for COMT and SOD2 and subsequently validated by 
Sanger sequencing as described in section 3.3.5 if the variants were predicted to be damaging by 
either one of the algorithms. The novel variants identified in the CYP genes from the exome data 
were not investigated further due to the genes’ complex polymorphic nature and high sequence 
similarity which hampers next-generation sequencing (NGS) capabilities (Drögemöller et al., 2013).   
3.3 Experimental Procedures for SNP Genotyping and Sanger DNA Sequencing 
3.3.1 Amplification of SNP Regions in Pharmacogenes 
3.3.1.1 Primers for Polymerase Chain Reaction (PCR) 
For the majority of SNPs, primer sequences were available from previous studies. The primer 
sequences are shown in Table 3 and allowed for the amplification of the regions surrounding the 
variants of interest, under conditions described in Table 4. In order to design genotyping assays for 
the novel variants identified in COMT and SOD2, the reference sequences for the relevant genomic 
regions were obtained from the Ensembl Genome Browser (Cunningham et al., 2014) (Ensembl Gene 
ID ENSG00000093010 and ENSG00000112096, respectively). The novel variant present in COMT 
was located in close proximity to both rs6269 and rs4633 and was thus amplified with primers used 
for the region including these SNPs, and subsequently genotyped using restriction enzymes as 
described in section 3.3.3. For the novel variant present in SOD2 primers were designed in a web-
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based primer design application by Integrated DNA Technologies (IDT - PrimerQuest Input), using 
the OligoAnalyzer 3.1 and PrimerQuest computational tools and a genotyping assay was 
subsequently designed for the amplification of the region containing the novel variant for SOD2 by 
means of the allele-specific PCR method as described in section 3.3.1.5.   
3.3.1.2 PCR Conditions 
PCR was used to amplify regions of interest within pharmacogenes from patient gDNA previously 





, London, UK). The remaining reagents were optimized 
specifically for each SNP as shown in Table 4. PCR amplifications were performed using the 
GeneAmp
®
 PCR Systems 2700 (Applied Biosystems
TM
, California, USA) and the cycle conditions 
are displayed in Table 5. 
Table 3. Primer sequences used in experimental procedures, including expected amplicon sizes and genetic variation 
SNPs Amplicon 
Size (bp) 
Primer Sequence (5’-3’) Polymorphism Reference 
COMT 
1rs9617850 413 F – TGCATCACGTGGGTTAGCAGAGAA 
R – TTCATGGCTGAACTGCCTTCCTCA 
G>A (Wright et al., 
2012) 
rs9606186 486 F – TCACTGCACATAGTGCCACTCTCA 
R – TCATGGCAGACGCTAGGCTCTACTG 
G>C (Wright et al., 
2012) 
rs2075507 681 F – CTCTGGCGGAAAGGAAT 
R – CCCACAGGCAGTGAGTGTA 
A>G (Wright et al., 
2012) 
rs45551837 774 F – GACTGCCTCCCAGAACTCTGTT 
R – CATACCGGCCTCTTGGTCTA 
G>A (Wright et al., 
2012) 
rs45536341 678 F – TCAGCACAGCAGGACCTTAGACAA 
R – ACCTCAGCTTTCCACAAGGAGTCT 
C>T (Wright et al., 
2012) 
1rs737865 350 F – CTGCCCTGCTAACAGACCTGC 
R – GTGGCAAACCCAGATCAGTTGG 





499 F – TTCTGAACCTTGCCCCTCTgC 





(Wright et al., 
2012) 
Stellenbosch University  https://scholar.sun.ac.za





295 F – GGGATCCAAGTTCCCCTCTC 





(Wright et al., 
2012) 
rs9332377 332 F – AGCATCCTATGAGGTTTCTCC 
R – AGTGCCAGGAACTCAGCCTTA 
C>T  (Wright et al., 
2012) 
1rs165599 414 F – ACCTCTCTGAACTGCAACACTGGA 
R – TGTGAATGCTGGCTGACTCCTCTTC 
G>A (Wright et al., 
2012) 
DRD2 
1rs1799732 303 F – ACTGGCGAGCAGACGGTGAGGACCC 
R – TGCGCGCGTGAGGCTGCCGGTTCGG 
Del>C (Arinami et al., 
1997) 
1rs1079597 459 F – GATACCCACTTCAGGAAGTC 
R – GATGTGTAGGAATTAGCCAGG  
C>T (Wu et al., 
2000) 
1rs1800497 310 F – CCGTCGACCCTTCCTGAGTGTCATCA 
R – CCGTCGACGGCTGGCCAAGTTGTCTA 
G>A 2(E713K)  (Wu et al., 
2000) 
rs6275 494 F – AGGAGCTGGAGATGGAGATGCT 
R – TGCCCATCTGTAAAGTGAGCACAA 
T>C 3(C939T) (Röhrich, 
2009) 
DRD3 
rs6280 463 F – GCTCTATCTCCAACTCTCACA 
R – AAGTCTACTCACCTCCAGGTA 
G>A 2(G9S) (Hitzeroth et 
al., 2007) 
HTR2A 
rs6311 469 F –  AACCAACTTATTTCCTACCAC 





rs6313 345 F –  TCTGCTACAAGTTCTGGCTT 
R –  CTGCAGCTTTTTCTCTAGGG 
C>T 3(C102T) (Röhrich, 
2009) 
SOD2 
rs4880 91 F –  CCAGCAGGCAGCTGGCACCG 




rs372173830 575 First amplification 
F –   CCAGGTGTCGCATTCTGATGTT 
R –   CAACAGTGAGATCTGTCTCA 
C>G 2(E133D) novel 
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406 Second amplification (nested) 
F1 –  GTTCCTTTGACAAGTTTAAGGAG 
F2 –  GTTCCTTTGACAAGTTTAAGGAC 




596 F –  GCTACACATGATCGAGCTATAC 
R –  CAGGTCTCTTCACTGTAAAGTTA 
G>A (Nakajima et 
al., 1999) 
rs762551 (*1F) 519 F –  TGGAGTGGTCACTTGCCTCT 
R –  CTGGCTCATCCTTGACAGT 
C>A (Tiwari et al., 
2005) 
CYP2D6 
CYP2D6*1 6.6 kb F – ATGGCAGCTGCCATACAATCCACCTG 
R – CGACTGAGCCCTGGGAGGTAGGTAG 
Reference 
sequence 
(Wright et al., 
2010) 
CYP2D6*1xN 3.5 kb F – CCATGGAAGCCCAGGACTGAGC 
R – CGGCAGTGGTCAGCTAATGAC 
Duplication (Wright et al., 
2010) 
Duplication test 8.6 kb F – CGGCAGTGGTCAGCTAATGAC 
R – CCAGAAGGCTTTGCAGGCTTCAG 
5’ duplication (Gaedigk et al., 
2007) 
CYP2D6*5 3.5 kb F – ACCAGGCACCTGTACTCCTCA 
R – GCATGAGGAAGGCACCCAGAC 





184/202 F – GTGGGTGATGGGCAGAAG 
R – GAGGGTCGTCGTACTCGAA 
G>A and 18bp 
insertion, 
respectively 
(Wright et al., 
2010) 
rs5030655 (*6) 600 F – TGTGCTGTAAGCTCAGTGTGGGT 
R – GAGGGTCGTCGTACTCGAA 
T>Del (Wright et al., 
2010) 
CYP2D6*13 5kb F – TCCGACCAGGCCTTTCTACCAC 
R – ACTGAGCCCTGGGAGGTAGGTAG 
2D7/2D6 
Hybrid 
(Wright et al., 
2010) 
1Polymorphisms that have been genotyped previously (Higgins, 2011) but still tested for association analyses in this study  




3.3.1.3 Long-range PCR for the Detection of CYP2D6 Alleles 
Analysis of the duplication and deletion of the 6.6 kb CYP2D6 gene was performed using long-range 
PCR as described by Wright et al. (2010). This gene was amplified using ~20 ng DNA, 0.4 U KAPA 
Long Range DNA Polymerase (KAPABiosystems
TM
, Cape Town, South Africa), 1x KAPA Long 
Range 5x buffer, 0.4 M CYP2D6 primers for the 6.6 kb fragment and 0.3 M primers for the 
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fragment tested specifically for either the duplication or deletion, 2 mM KAPA Long Range MgCl2 
and 0.4 mM dNTPs, and 1 M Betaine (Sigma-Aldrich (Pty) Ltd, Aston Manor, South Africa) with a 
final reaction volume of 8 l. Samples were amplified by conditions described in Table 5 after pre-
setting the thermal cycler programme to heat block at 85C using the GeneAmp
®
 PCR Systems 2700 
(Applied Biosystems
TM
, California, USA). The nature of gene duplications were further investigated 
by amplifying the duplicated gene under the same conditions using 2.5 mM KAPA Long Range 
MgCl2, and 0.4 M primers, and genotyping these fragments by restriction fragment length 
polymorphism (RFLP) PCR for the allele-defining SNPs for CYP2D6*4 and CYP2D6*6 (Table 6), 
and by PCR for CYP2D6*40 (See Table 4 and Table 5 for reagent concentrations and conditions, 
respectively). Specific exons containing SNPs of interest were amplified by nested PCR using 
~1000x dilutions of long-range products and subsequently genotyped using RFLP-PCR as described 
in Table 6 and visualized as described in section 3.3.2.   
3.3.1.4 Hybrid PCR for the Detection of CYP2D6 Hybrid Gene 
CYP2D6 is known to result in hybrid pseudogenes (CYP2D7/CYP2D6) from recombination activities 
(Black et al., 2012). Patient samples that tested homozygous for all SNPs genotyped were therefore 
selected for hybrid testing. The 1000x diluted product obtained from the long-range PCR described in 
section 3.3.1.3 was used as a template for this assay that was performed in two separate reactions. 
The first reaction was performed as a control to amplify the 6.6 kb CYP2D6 gene as well as the 5 kb 
hybrid, CYP2D7/CYP2D6, and the second reaction was specific for the hybrid only to confirm no 
spurious amplification took place in the first run, using the specified primers indicated in Table 3. 
Concentrations of reaction mixtures were the same as described for the long range PCR, using 1.5 
mM KAPA Long Range MgCl2. Products were visualized as described in section 3.3.2. 
3.3.1.5 Allele-specific PCR for the Detection of rs372173830 in SOD2 
The allele-specific PCR method was employed for investigating the novel SNP in SOD2, 
rs372173830, identified from the exome sequencing data. Two sets of primers (Table 3) were 
designed, of which the first set was used to amplify the region of interest containing the SNP, and the 
second set was used for amplification of either the wild-type or variant allele by means of a nested 
PCR, narrowing down the region of interest and using a 1 in 50 µl dilution of the previously 
amplified product as a template. All samples therefore underwent three successive rounds of PCRs to 
successfully genotype this SNP using reagent concentrations described in Table 4 and PCR 
conditions described in Table 5.  
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rs9617850 1.5 0.4 0.4 - 25 




rs2075507 1.5 0.4 0.4 - 25 












rs6269, rs4633, rs373611092 1 0.4 0.4 - 30 
rs4818, rs4680 2.5 0.4 0.4 - 25 
rs9332377 1.5 0.4 0.4 - 25 
rs165599 2 0.4 0.2 - 15 
DRD2 
rs1799732 1.5 0.4 0.2 1M Betaine 20 








rs6275 1.5 0.4 0.5 - 15 
DRD3 rs6280 3 1 0.3 - 15 
HTR2A 
rs6311 1.5 0.4 0.5 - 15 
rs6313 1.5 0.4 0.5 - 15 
SOD2 




rs372173830 – First and 
second amplification 
1.5 0.4 0.5 - 15 
CYP1A2 
rs2069514 (*1C),  rs762551 
(*1F) 




1.5 0.4 0.4 - 25 
rs5030655 (*6) 2 0.4 0.2 - 25 
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3.3.2 Visualization of PCR products 
Each fragment was visualized by electrophoresis on 1, 1.5 or 3% (w/v), agarose gels (Appendix A) 
depending on fragment sizes and stained with 0.5 µg/ml ethidium bromide, in 1x TBE buffer 
(Appendix A), using molecular weight markers (Hyperladder I, IV or V, Bioline
TM
, London, UK) 
relevant to the expected size of the fragment. The fragments were subsequently loaded onto the gel 
using 5 µl CRESOL Loading Buffer (Appendix A). Fragments were allowed to migrate through the 
gel for 30 minutes at 120 V, followed by visualization under ultra-violet light at 260 nm with a 
MultiGenius Bio Imaging Capture System (Syngene, Cambridge, UK). Long-range and hybrid 
products were visualized on 0.6% (w/v) agarose gel using a molecular weight marker of 200 bp 
(Hyperladder I, Bioline
TM
, London, UK).  
3.3.3 Restriction Fragment Length Polymorphism (RFLP) Analysis 
Amplified fragments were subsequently used for PCR-RFLP analysis using the restriction enzymes 
and conditions as shown in Table 6. Relevant restriction enzymes were identified from an online 
application tool, RestrictionMapper version 3 (http://www.restrictionmapper.org/). Digests were all 
performed on the GeneAmp
®
 PCR Systems 2700 (Applied Biosystems
TM
, California, USA). 
Fragments were separated on agarose gels depending on the size of the respective fragments and 
stained with 0.5 µg/ml ethidium bromide for visualization under ultra-violet light with a MultiGenius 
Bio Imaging Capture System (Syngene, Cambridge, UK). Positive controls, if available, were used to 






 probe-based assays (Applied Biosystems
TM
, California, USA) were performed for the SNPs 
in COMT rs5748489 and rs2020917 (Higgins, 2011), and DRD2 rs6277 (Welham, 2015), since these 
SNPs do not create or abolish recognition sequences of known restriction enzymes. The reactions for 
COMT rs5748489 and rs2020917 were carried out using 15 ng gDNA, 1x TaqMan
®
 probes and 1x 
TaqMan
®
 Genotyping Master Mix. For DRD2 rs6277, the reaction was performed using 30 ng 
gDNA, 1x ROX High Reference Dye, 20x TaqMan
®
 SNP assay (Applied Biosystems
TM
, California, 
USA) and 1x KAPA Probe Fast qPCR Master Mix (KAPABiosystems
TM
, Cape Town, South Africa). 
All reactions were performed using a final volume of 10 l in 96-well plates. These reactions were 
performed on a StepOnePlus™ Real-Time PCR System (Applied Biosystems
TM
, California, USA) 
using the conditions described by the manufacturer. The genotyping was performed using the 
Sequence Detection System (SDS) Software (Applied Biosystems
TM
, California, USA) with an 
autocaller confidence level of 95%. 
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3.3.5 Bi-directional Sanger Sequencing 
Due to its functional consequence, the novel variant in COMT (rs373611092) was selected for 
sequencing. PCR products were bi-directionally sequenced using Sanger sequencing to confirm the 
presence of this variant as called by the exome sequencing. PCR products, representing the different 
genotype classes, where available, were purified using the SureClean Protocol (Bioline
TM
, London, 
UK) and sample concentrations were measured on the Nanodrop spectrophotometer (NanoDrop
®
 
ND-100, Nanodrop Technologies Inc., Wilmington, Delaware, USA) at a wavelength of 260 nm 
followed by preparation of the sequencing reaction as described in the BigDye
®
 Terminator v3.1 
Cycle Sequencing Kit Manual (Applied Biosystems
TM
, California, USA). The samples were analyzed 
by capillary electrophoresis on a 3130xl Genetic Analyser (Applied Biosystems
TM
, California, USA) 
at the Central Analytical Facility, Stellenbosch University and results were aligned to the relevant 
reference sequences with the sequence alignment programme, BioEdit (Ibis Biosciences, Carlsbad, 
California, USA).  
Table 5. PCR cycle conditions used 




rs4633, rs373611092 and 
rs9332377 
94°C 3 min; 40 cycles of 94°C 15 sec, 60°C 
15 sec and 72°C 30 sec; 72°C 5 min 
 
(Wright et al., 2012) 
rs9606186 94°C 3 min; 10 cycles of 94°C 15 sec, 60°C 
15 sec and 72°C 30 sec; 30 cycles of 94°C 15 
sec, 55°C 15 sec and 72°C 30 sec; 72°C 5 
min 
(Wright et al., 2012) 
rs2075507 and 
rs45536341 
94°C 3 min; 40 cycles of 94°C 15 sec, 55°C 
15 sec and 72°C 30 sec; 72°C 5 min 
(Wright et al., 2012) 
rs4818 and rs4680 94°C 3 min; 40 cycles of 94°C 15 sec, 66°C 
15 sec and 72°C 30 sec; 72°C 5 min 
 
(Wright et al., 2012) 
rs165599 94°C 3 min; 10 cycles of 94°C 15 sec, 68°C 
15 sec and 72°C 30 sec; 30 cycles of 94°C 15 
sec, 62°C 15 sec and 72°C 30 sec; 72°C 5 
min 
(Wright et al., 2012) 
DRD2 
rs1799732 95ºC 4min; 35 cycles of 95ºC 1 min, 55ºC 
1min and 72ºC 1,5min; 72ºC 5min 
(Breen et al., 1999) 
rs1079597 94ºC 4 min; 10 cycles of 94ºC 30 sec, 65ºC 
30 sec and 72ºC 30 sec; 25 cycles of 94ºC 30 
sec, 55ºC 30 sec and 72ºC 30 sec; 72ºC 4 
min 
(Röhrich, 2009) 
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rs1800497 94ºC  4 min; 10 cycles of 94ºC 30 sec, 65ºC 
30 sec and 72ºC 30 sec; 25 cycles of 94ºC 30 
sec, 55ºC 30 sec and 72ºC 30 sec; 72ºC 4 
min 
(Röhrich, 2009) 
rs6275 94ºC 3 min; 40 cycles of 94ºC 15 sec, 60ºC 
15 sec and 72ºC 30 sec; 72ºC 5 min 
(Röhrich, 2009) 
DRD3 
rs6280 94ºC 5 min; 35 cycles of 94ºC 30 sec, 57ºC 
30 sec and 72ºC 45 sec; 72ºC 7 min 
(Hitzeroth et al., 2007) 
HTR2A 
rs6311 94ºC 5 min; 30 cycles of 94ºC 20 sec, 62ºC 
20 sec and 72ºC 20 sec; 72ºC 10 min 
(Röhrich, 2009) 
rs6313 94ºC 5 min; 30 cycles of 94ºC 20 sec, 60ºC 
20 sec and 72ºC 20 sec; 72ºC 10 min 
(Röhrich, 2009) 
SOD2 
rs4880 94ºC 3 min; 35 cycles of 94ºC 1 min, 60ºC 1 
min and 72ºC 1 min; 72ºC 5 min 
(Chistyakov et al., 2001) 
rs372173830 First amplification: 94ºC 3 min; 35 cycles of 
94ºC 20 sec, 62ºC 20 sec and 72ºC 30 sec; 
72ºC 5 min 
Second amplification: 94ºC 3 min; 19 cycles 
of 94ºC 15 sec, 60ºC 15 sec and 72ºC 30 sec; 




95ºC 5 min; 35 cycles of 95ºC 45 sec, 56ºC 
45 sec and 72ºC 1 min; 72ºC 7 min 
(Truter, 2007) 
rs762551 (*1F) 
95ºC 5 min; 35 cycles of 95ºC 30 sec, 58ºC 





95°C 5 min; 35 cycles of 95°C 15 sec and 
68°C 10 sec; 68°C 7 min 
(Wright et al., 2010) 
Duplication test 95°C 5 min; 35 cycles of 95°C 15 sec and 
68°C 10 sec; 68°C 9 min 
(Gaedigk et al., 2007) 
rs3892097/ rs72549356 
(*4/*40) 
94°C 3 min; 35 cycles of 94°C 15 sec, 55°C 
15 sec and 72°C 30 sec; 72°C 5 min 
(Wright et al., 2010) 
rs5030655 (*6) 94°C 3 min; 40 cycles of 94°C 15 sec, 55°C 
15 sec and 72°C 30 sec; 72°C 5 min 
(Wright et al., 2010) 
CYP2D6*13 95°C 2 min; 35 cycles of 95°C 15 sec, 67°C 
10 sec; 68°C 7 min 
(Wright et al., 2010) 
*Conditions for reactions were optimized. 
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Electrophoresis  for 
fragment separation 




rs9617850 BsaAI (NEB) 3 - 37°C, 16 hr GG 
GA 
AA 
275, 130, 8 
405, 275, 130, 8 
405, 8 
2% Agarose Gel 
80 V for 1 hr 
(Wright et al., 
2012) 
rs9606186 BsrI (NEB) 3 - 65°C, 2 hr 
(inactivation 
step of 80°C 




320, 76, 54, 36 
320, 295, 76, 54, 36, 25 
295, 76, 54, 36, 25 
3% Agarose Gel 
80 V for 2 hr and 20 min 








407, 274, 230, 177 
274, 230, 177 
2% Agarose Gel 
80 V for 1 hr 
(Wright et al., 
2012) 
rs45551837 TaqαI (NEB) 4 BSA 
(100µg/ml) 
65°C, 2 hr GG 
GA 
AA 
364, 251, 159 
410, 364, 251, 159 
410, 364 
2% Agarose Gel 
80 V for 1 hr 
(Wright et al., 
2012) 
rs45536341 BsaHI (NEB) 2 BSA 
(100µg/ml) 




678, 457, 221 
678 
2% Agarose Gel 
80 V for 1 hr and 45 min 
(Wright et al., 
2012) 




300, 259, 50, 41 
259, 50, 41 
2% Agarose Gel 
80 V for 1 hr and 20 min 
(Wright et al., 
2012) 
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rs6269 TaqαI (NEB) 2 BSA 
(100µg/ml) 




499, 479, 20 
479, 20 
4% Agarose Gel 
80 V for 3.5 hr 
(Wright et al., 
2012) 




499, 305, 194 
499 
2% Agarose Gel 
80 V for 1.5 hr 
(Wright et al., 
2012) 




499, 392, 107 
499 
2% Agarose Gel 
80 V for 1.5 hr 
*NA 
rs4818 MboI (NEB) 5 - 37°C, 16 hr CC 
CG 
GG 
126, 103, 64, 2 
126, 114, 103, 64, 12, 2 
114, 103, 64, 12, 2 
15% Polyacrylamide Gel 
200 V for 1 hr 
(Wright et al., 
2012) 
rs4680 NlaIII (NEB) 3 BSA 
(100µg/ml) 
37°C, 16 hr GG 
GA 
AA 
151, 114, 30 
151, 114, 96, 30, 18 
151, 96, 30, 18 
15% Polyacrylamide Gel 
200 V for 1 hr 
(Wright et al., 
2012) 




332, 310, 22 
310, 22 
4% Agarose Gel 
80 V for 4 hr 
(Wright et al., 
2012) 




414, 376, 38 
414 
2.5% Agarose Gel 
80 V for 2 hr and 45 min 
(Wright et al., 
2012) 
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rs1799732 BstNI (NEB) 5 
BSA 
(100µg/ml) 





160, 144, 303 
303 
2.5% Agarose Gel 
80 V for 1 hr 
(Arinami et al., 
1997) 
rs1079597 Taq1α (NEB) 2 
BSA 
(100µg/ml) 





459, 267, 192 
459 
2% Agarose Gel 
80 V for 1 hr 
(Wu et al., 2000) 
rs1800497 Taq1α (NEB) 2 
BSA 
(100µg/ml) 





310, 180, 130 
310 
2% Agarose Gel 
80 V for 1 hr 
(Wu et al., 2000) 




274, 113, 107 
381, 274, 113, 107 
381, 113 
2% Agarose Gel 
80 V for 1 hr 
(Röhrich, 2009) 





463, 260, 203 
463 
15% Polyacrylamide Gel 
200 V for 1 hr 
(Hitzeroth  et al., 
2007) 
HTR2A 





469, 245, 224 
469 
2% Agarose Gel 
80 V for 1 hr 
(Röhrich, 2009) 





342, 217, 125 
342 
2% Agarose Gel 
80 V for 1 hr 
(Röhrich, 2009) 
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SOD2 rs4880 AgeI (NEB) 3 - 









91, 74, 17 
91 
4% Agarose Gel 
80 V for 1 hr 










596, 464, 132 
464, 132 
1.5% Agarose Gel 
80 V for 1 hr and 20 min 
(Truter, 2007) 
rs762551 





519, 372, 147 
519 
1.5% Agarose Gel 





BstNI (NEB) 5 BSA 
(100µg/ml)- 




184, 98, 86 
184 
2% Agarose Gel 
80 V for 1 hr 








600, 350, 219, 30 
350, 219, 30 
2% Agarose Gel 
80 V for 1 hr 
*NA 
NA: not applicable 
*Conditions for reactions were optimized. 
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3.4 Statistical Analysis 
3.4.1 Genotype and Allele Distributions and CYP2D6 Activity Scores 
Differences in allele and genotype frequencies were determined for all variants, including 
analysis for deviations from Hardy-Weinberg Equilibrium (HWE) using SNPStats (Solé et al., 
2006). P values ≤ 0.01 were regarded as significant for HWE. Minor allele frequencies (MAF) for 
the different FES population groups were compared to MAF of the African, American, East 
Asian and European populations retrieved from the 1000 Genomes Project (Abecasis et al., 
2012). CYP minor allele frequencies for the FES populations were compared to frequencies 
retrieved from The Human Cytochrome P450 (CYP) Allele Nomenclature Database (Sim and 
Ingelman-Sundberg, 2010) of African, African American, East Asian and European populations. 
Haplotypes and inferred frequencies were calculated in R (Ihaka and Gentleman, 1996). LD plots 
for significant haplotypes were constructed in Haploview 3.31 (Barret et al., 2005). Activity 
scores for CYP2D6 were calculated to deduce phenotypic information of metabolizer groups as 
described by Gaedigk et al. (2008) using Model A in Table 7.  
Table 7. Values assigned to alleles in AS-Model A (Gaedigk et al., 2008). Reprinted with permission from Wiley 
Value assigned to allele Alleles - AS-Model A  
0 *3, *4, *4xN, *5, *6, *7, *16, *36, *40, *42, *56B 
0.5 *9, *10, *17, *29, *41, *45, *46   
1 *1, *2, *35, *43, *45xN   
2 *1xN, *2xN, *35xN    
AS: activity score. The AS of a genotype is the sum of the values assigned to each allele (e.g., CYP2D6*1/*1 and CYP2D6*2/*5 
genotypes have AS of 2 and 1, respectively).  
3.4.2 Association Testing 
Statistical analyses were performed in R and various R packages, including genetics v3.0.3 (Ihaka 
and Gentleman, 1996) by a qualified statistician. Mixed model repeated measures analysis was 
used to determine associations between genotyped SNPs, haplotypes, and activity scores across 
changes in longitudinal PANSS scores over twelve months. Analyses were performed by 
correcting for age, gender, proportion ancestry and baseline PANSS scores. Proportion ancestry 
was calculated using the ancestry informative markers (AIMs) data for the entire study cohort and 
1000 Genomes populations using ADMIXTURE (Alexander et al., 2009). These data were 
previously obtained in our study group to correct for population stratification (Drögemöller et al., 
2013). Significant associations with genotyped SNPs were tested with additive, dominant and 
recessive inheritance models by which the strength of the associations was assessed and effect 
sizes (ES) with 95% confidence intervals (CI) are reported. Unadjusted patterns of the 
associations with a change in PANSS scores and each SNP were determined and presented in 
graphs. P values ≤ 0.01 were regarded as significant. 
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4 CHAPTER 4: RESULTS 
4.1 Selection of Variants 
After literature mining and quality control, a total of 31 variants in seven genes that met the 
criteria for candidate pharmacogenes were prioritized for inclusion in this study (Table 8). 
Evaluation of the exome data revealed a total of eighteen missense variants in six of the seven 
genes, predominantly present in CYP2D6 (Table 9). As a result of information that became 
available after the initial characterization of the variants identified from the exome data for the 
CYP genes, including the novel variants reported, it was decided not to include these in further 
analyses due to the unreliability of NGS data for these genes (Drögemöller et al., 2013). 
Exclusion of all CYP variants left a total of eight missense variants in COMT, DRD3, HTR2A and 
SOD2 of which six have previously been reported and two are novel. Novel variants submitted to 
NCBI dbSNP were assigned the rs IDs, COMT rs373611092 and SOD2 rs372173830, using the 
submitter handle “WARNICH_LAB”. PolyPhen-2 and SIFT algorithms predicted COMT 
rs373611092 to damage the resulting gene product (SIFT score = 0.015) and SOD2 rs372173830 
to be benign or tolerating (SIFT score = 0.48). Bi-directional sequencing was performed to 
confirm the single novel variants that predicted functional damage (Appendix B1). 
Finally 33 variants were selected for genotyping in the FES cohort. These variants consisted of 31 
variants prioritized from the literature and the two novel SNPs identified from the exome data in 
COMT (rs373611092) and SOD2 (rs372173830). Examples of the PCR-RFLP and TaqMan
®
 
analyses for each of the SNPs are depicted in Appendix B2 and Appendix B3, respectively. 
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Table 8. Candidate pharmacogenes associated with antipsychotic treatment outcome (variants listed in order from 5’-3’) 
UTR: untranslated region 








Di Giorgio et al., 2009; Gerretsen et al., 2009; Lencz and Malhotra, 2009; Blanc et al., 2010; Foster et al., 
2010; Gesteira et al., 2010; Šagud et al., 2010;  Arranz and Munro, 2011; Arranz et al., 2011; Burdick et 
al., 2011; Cacabelos et al., 2011; Chowdhury et al., 2011; Lee and Kang, 2011; Zhang and Malhotra, 
2011; Reynolds, 2012; Vyas et al., 2012;  Wright et al., 2012  
rs9606186 upstream 







rs4633 synonymous codon (C186T) 
rs4818 synonymous codon (G408C) 
rs4680 missense (V158M) 
rs9332377 intron 
rs165599 3’ UTR 
CYP1A2 
rs2069514 (*1C)  upstream 
Treatment response, 
Movement disorder 
Gerretsen et al., 2009; Foster et al., 2010; Gesteira et al., 2010; Kores Plesničar, 2010; Lohoff and Ferraro, 
2010; Tandon et al., 2010; Arranz and Munro, 2011; Arranz et al., 2011; Lee and Kang, 2011; Zhang and 
Malhotra, 2011 
rs762551 (*1F) intron 
CYP2D6 
CYP2D6*1xN gene duplication 
Treatment response, 
Movement disorder, 
Weight gain, QT 
prolongation 
Gerretsen et al., 2009; Foster et al., 2010; Gesteira et al., 2010; Kores Plesničar, 2010; Wright et al., 2010 
Arranz and Munro, 2011; Arranz et al., 2011; Balt et al., 2011; Chowdhury et al., 2011; Lee and Kang, 
2011; Risselada et al., 2011; Zhang and Malhotra, 2011; Lett et al., 2012  
CYP2D6*5 gene deletion 
rs3892097 (*4) splice acceptor 
rs72549356 (*40) 18 bp insertion 
rs5030655 (*6) frameshift 
CYP2D6*13 
(2D7/2D6) 
gene hybrid structures 
DRD2 






Gerretsen et al., 2009; Lencz and Malhotra, 2009; Blanc et al., 2010; Foster et al., 2010; Gesteira et al., 
2010; Kores Plesničar, 2010; Shiroma et al., 2010; Steimer, 2010; Arranz and Munro, 2011; Arranz et al., 
2011; Balt et al., 2011; Burdick et al., 2011; Chowdhury et al., 2011; Lee and Kang, 2011; Risselada et al., 
2011; Zhang and Malhotra, 2011; Lett et al., 2012 
rs1079597 intron 
rs1800497 (ANKK1) missense (E713K) 
rs6275  synonymous codon (C939T) 
rs6277  synonymous codon (C957T) 
DRD3 rs6280 missense (G9S) 
Treatment response, 
Movement disorder 
Di Giorgio et al., 2009; Gerretsen et al., 2009; Lencz and Malhotra, 2009; Blanc et al., 2010; Foster et al., 
2010; Gesteira et al., 2010; Kores Plesničar, 2010; Steimer, 2010; Tandon et al., 2010; Arranz and Munro, 
2011; Arranz et al., 2011; Cacabelos et al., 2011; Chowdhury et al., 2011; Lee and Kang, 2011; Zhang and 
Malhotra, 2011; Reynolds, 2012 
HTR2A 
rs6311 upstream (A-1438G) Treatment response, 
Movement disorder, 
Weight gain 
Gerretsen et al., 2009;   Lencz and Malhotra, 2009; Blanc et al., 2010;  Foster et al., 2010; Gesteira et al., 
2010; Kores Plesničar, 2010;  Lohoff and Ferraro, 2010; Steimer, 2010;  Tandon et al., 2010; Arif and 
Mitchell, 2011; Arranz et al., 2011; Balt et al., 2011; Cacabelos et al., 2011; Chowdhury et al., 2011; 
Risselada et al., 2011; Zhang and Malhotra, 2011; Lett et al., 2012; Reynolds, 2012 
rs6313 synonymous codon (C102T) 
SOD2 rs4880 missense (V16A) Movement disorder Hitzeroth et al., 2007; Arranz et al., 2011; Chowdhury et al., 2011; Lee and Kang, 2011 
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Table 9: Known and novel functional variants identified from previously generated exome data 
(variants listed in order from 5’-3’) 
Known Variants     
Gene Locus Effects PolyPhen-2 SIFT 
COMT rs4680 V158M Benign Damaging 
CYP1A2 
rs17861157 S298R Benign Damaging 
rs144148965 D436N Benign No score 
CYP2D6 
rs1135840 T486S Benign Tolerated 
rs59421388 V338M Probably damaging Damaging 
rs16947 C296R Benign Tolerated 
rs28371717 A237S Benign Tolerated 
rs61736512 V136I Benign Tolerated 
rs28371696 R26H Benign Tolerated 
DRD3 rs6280 G9S Benign Tolerated 
HTR2A 
rs6314 H425Y Benign Tolerated 
rs6304 I197V Benign Tolerated 
rs6312 D49N No score No score 
SOD2 rs4880 V16A Benign Tolerated 
 
Novel Variants 
Gene Locus Effects PolyPhen-2 SIFT 
COMT  rs373611092 M90V Probably damaging Damaging 
CYP2D6 
1
22:42522641 H477N Benign Tolerated 
2
rs769157652 E410K Benign Tolerated 
SOD2 rs372173830 E133D Benign Tolerated 
1Novel variant chromosome position. No rs ID is available for this variant yet 
2Variant was detected as novel at the start of this study, but recently reported in the dbSNP database by another research group. CYP 
variants were excluded from further analyses due to unreliable data obtained from NGS 
4.2 Frequency Data for SNPs 
Allele and genotype frequencies were calculated in the FES cohort for each of the subpopulations 
in this cohort. Genotype frequencies are displayed in Appendix C for each of the SNPs evaluated. 
MAF for each SNP across different populations in the FES cohort were calculated and compared 
to the MAF of the African (AFR), American (AMR), Asian (ASN) and European (EUR) 
populations from the 1000 Genomes Project database (Table 10). None of the SNPs deviated 
from HWE in any of the population groups (Appendix D).   
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Table 10: Minor allele frequency comparisons for SA FES populations and 1000 Genomes Project 
populations 
 SNPs Populations from SA FES cohort Populations from 1000 Genomes Project 
  Cau SAC Xh AFR AMR ASN EUR 
COMT 
rs9617850  0.19 0.26 0.46 0.43 0.19 0.10 0.20 
rs9606186  0.31 0.32 0.31 0.39 0.34 0.28 0.41 
rs5748489  0.31 0.28 0.15 0.24 0.32 0.28 0.41 
rs2075507  0.31 0.31 0.23 0.36 0.34 0.28 0.41 
rs45551837  0.00 0.03 0.15 0.11 0.02 0.06 0.00 
rs2020917  0.38 0.23 0.13 0.08 0.18 0.30 0.28 
rs45536341  0.00 0.01 0.00 0.01 0.00 0.00 0.00 
rs737865  0.38 0.26 0.12 0.13 0.18 0.29 0.28 
rs6269 0.19 0.34 0.31 0.37 0.31 0.34 0.41 
rs4633 0.50 0.41 0.27 0.29 0.38 0.27 0.50 
rs373611092 0.00 0.01 0.00 NA NA NA NA 
rs4818 0.31 0.28 0.19 0.17 0.30 0.34 0.40 
rs4680  0.50 0.38 0.23 0.28 0.38 0.28 0.50 
rs9332377  0.13 0.19 0.35 0.36 0.13 0.00 0.15 
rs165599  0.21 0.42 0.50 0.75 0.50 0.47 0.31 
DRD2 
rs1799732 0.06 0.29 0.54 0.57 0.16 0.14 0.08 
rs1079597  0.19 0.22 0.12 0.17 0.27 0.41 0.15 
rs1800497  0.21 0.33 0.35 0.39 0.31 0.41 0.19 
rs6275  0.75 0.40 0.19 0.34 0.61 0.47 0.69 
rs6277  0.56 0.16 0.00 0.06 0.33 0.06 0.54 
DRD3 
rs6280  0.63 0.42 0.12 0.18 0.57 0.69 0.66 
HTR2A 
rs6311 0.31 0.30 0.54 0.41 0.36 0.59 0.44 
rs6313  0.31 0.27 0.50 0.39 0.35 0.59 0.44 
SOD2 
rs4880 0.44 0.36 0.50 0.42 0.58 0.13 0.47 
rs372173830 0.00 0.05 0.04 NA NA NA NA 
CYP1A2 
rs2069514 (*1C) 0.00 0.19 0.31 0.31 0.36 0.28 0.02 
rs762551 (*1F) 0.25 0.35 0.50 0.44 0.24 0.33 0.32 
NA: not applicable as no data is available for novel SNPs; SA: South African; FES: First episode schizophrenia cohort; 
Cau: FES Caucasian; SAC: FES South African Coloured; Xh: FES Xhosa; AFR: African; AMR: American; ASN: 
Asian; EUR: European 
 
Frequencies for the CYP2D6 alleles in this study were compared to frequencies in the African 
(AF), American (AM), Asian (AS) and European (EU) populations from the Human CYP Allele 
Nomenclature database (Table 11), since the frequency data for some CYP alleles were not 
available on the 1000 Genomes Project database.  
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Table 11. Frequency comparisons for CYP2D6 alleles in the SA FES populations and the Human 
CYP Allele Nomenclature populations 
Alleles 
Populations from SA FES 
cohort 
Populations from the Human CYP Allele 
Database 
 Cau SAC Xh AF AM AS EU 
rs3892097 (*4) 0.25 0.09 0.08 0.04 0.11 0.00 0.19 
deletion (*5) 0.13 0.13 0.19 0.06 0.02 0.06 0.03 
rs5030655 (*6) 0.06 0.00 0.00 0.00 0.00 0.00 0.01 
rs72549356 (*40) 0.00 0.01 0.00 0.01 0.00 0.00 0.00 
duplication 
(*1xN) 
0.00 0.03 0.08 0.01 0.01 0.00 0.01 
CYP2D6*4xN 0.00 0.01 0.04 0.01 0.01 0.00 0.00 
SA: South African; CYP: Cytochrome P450; FES: first episode schizophrenia cohort; Cau: FES Caucasian; SAC: FES 
South African Coloured; Xh: FES Xhosa; AF: African; AM: American; AS: Asian; EU: European 
The CYP2D6 activity score distribution for each population in the FES cohort is depicted in 
Figure 5, where most individuals for all three FES populations were assigned the value 1 and 2, 
denoting IM/EM phenotypes. Only a small number of individuals (less than 10) were classed as 
PMs (AS = 0) and UMs (AS = 3).  None of the Xhosa individuals displayed PM phenotypes and 
none of the Caucasian individuals exhibited UM phenotypes.  
 
Figure 5: Individuals in SA FES cohort classed into metabolizer groups based on Activity Score. AS: Activity 
score; FES: first episode schizophrenia; Xh: Xhosa; SAC: South African Coloured; Cau: Caucasian 
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4.3 Association Tests 
4.3.1 SNP associations with Treatment Outcome 
Changes in PANSS scores across twelve months, measured at regular intervals throughout this 
time period, were used to assess treatment outcome. Tests were performed for genotyped SNPs, 
calculated CYP2D6 activity scores, and additive allelic models of the SNPs and the changes in 
PANSS scores over twelve months, adjusting for age, gender, proportion ancestry and baseline 
PANSS scores, where P ≤ 0.01 was regarded as significant. Table 12 shows the significant P 
values in the highlighted cells obtained from the mixed model repeated measures analyses for the 
tests of association between individual SNPs and a change in PANSS scores over time. Apart 
from the significant associations observed between variants in COMT and DRD2 and change in 
PANSS negative scores, additional variants surpassing the significance threshold were considered 
for nominal associations (P ≤ 0.05) (Table 12). The effect estimates of these SNP associations 
were further investigated (Table 13) to determine the mode of inheritance that best fitted these 
significantly associated variants. The results from the complete data set can be found in Appendix 
E1 and Appendix E2. None of the significant associations survived Bonferroni corrections for 
multiple testing.  
From the fifteen SNPs investigated in the COMT gene, statistical data revealed the significant 
associations for two of the SNPs with changes in PANSS negative scores after twelve months of 
treatment (Table 12), a synonymous variant (rs4633) and intronic variant (rs9332377). Both these 
variants acted in an additive manner. In the case of rs4633, each copy of the T allele was 
associated with an improved treatment outcome for PANSS negative scores [P = 0.0080, ES = -
0.17 95% CI (-0.30 to -0.04)], while statistical analysis of rs9332377 revealed that each copy of 
the T allele of this variant was associated with worse treatment outcome [P = 0.0006, ES = 0.25 
95% CI (0.11 to 0.39)] (Table 13).  
Two of the five SNPs present in the upstream region (rs1799732) and intron 1 (rs1079597) of 
DRD2 were also significantly associated with PANSS negative scores when the genotypic model 
was used. These associations were not observed when allelic models were investigated (Table 
12). Interestingly, further analysis of the “best fit” inheritance model revealed that the genotypic 
model remained the “best fit” for rs1799732. In the case of rs1799732, when compared to C/C 
homozygous individuals, heterozygous individuals (C- vs CC) exhibited improved treatment of 
PANSS negative scores [P = 0.0004, ES = -0.19 95% CI (-0.38 to 0.00)], while homozygous 
del/del individuals (-- vs CC) showed worsening of PANSS negative scores each week after 
treatment [P = 0.0004, ES = 0.50 95% CI (0.15 to 0.86)] (Table 13). Further examination of 
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rs1079597 revealed that this variant acted in a recessive manner and was associated with a poor 
treatment outcome for PANSS negative scores [P = 0.0020, ES = 0.93 95% CI (0.34 to 1.53)] 
(Table 13).  
Unadjusted patterns for the significantly associated SNPs with changes in PANSS scores were 
determined and are illustrated with graphs in Appendix F. 
Table 12: Association tests with P values from mixed model repeated measures analyses for tests of association 
between genotyped SNPs and additive allelic model for the same SNPs and change in PANSS scores 
SNPs PANSSN PANSSP PANSSG PANSST 
Significant Associations (P ≤ 0.01) 
Genotypic Model 
COMT 
rs9332377 0.0026 0.0861 0.1187 0.0674 
DRD2 
rs1799732 0.0004 0.7079 0.0759 0.0282 
rs1079597 0.0082 0.6399 0.5887 0.1965 
Additive Allelic Model 
COMT 
rs4633 (T) 0.0080 0.9516 0.3482 0.1769 
rs9332377 (T) 0.0006 0.9638 0.3841 0.1174 
Nominal Associations (P ≤ 0.05) 
Genotypic Model 
COMT 
rs737865 0.8019 0.0201 0.0423 0.0955 
rs6269 0.0569 0.0433 0.1517 0.0356 
HTR2A 
rs6311 0.0298 0.2801 0.0842 0.0442 
CYP1A2 
rs762551 (*1F) 0.0101 0.7254 0.1983 0.2226 
Additive Allelic Model 
CYP2D6 
CYP2D6*1xN (duplication) 0.5831 0.0148 0.0233 0.0617 
rs3892097 (A) 0.6003 0.0281 0.9670 0.5438 
PANSSP: Positive symptoms total; PANSSN: Negative symptoms total; PANSSG: General psychopathology total; PANSST: Total 
score for all questions 
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Table 13: Significant P values from inheritance models estimating percentage change in PANSS scores after adjusting for covariates 
  P-value Mode of 
inheritance 
 % Change 
SNP Outcome Genotype Allelic "Best" Comparison per week (95% CI) 
Significant Associations (P ≤ 0.01) 
COMT 
rs4633 PANSSN 0.0293 0.0080 0.0080 Additive T Each T allele -0.17 (-0.30 to -0.04) 
rs9332377 PANSSN 0.0026 0.0006 0.0006 Additive T Each T allele 0.25 (0.11 to 0.39) 
DRD2 
rs1799732 PANSSN 0.0004 0.3669 0.0004 Genotype -C vs CC -0.19 (-0.38 to 0.00) 
      -- vs CC 0.50 (0.15 to 0.86) 
rs1079597 PANSSN 0.0082 0.1131 0.0020 Recessive AA vs AG+GG 0.93 (0.34 to 1.53) 
Nominal Associations (P ≤ 0.05) 
COMT 
rs737865 PANSSP 0.0201 0. 0495 0. 0092 Dominant AG+GG vs AA 0.32 (0.08 to 0.56) 
HTR2A 
rs6311 PANSSN 0.0298 0. 0975 0. 0170 Dominant AA+AG vs GG -0.22 (-0.40 to -0.04) 
 PANSST 0.0442 0.1268 0.0258 Dominant AA+AG vs GG -0.19 (-0.37 to -0.02) 
    CYP1A2    
rs762551 PANSSN 0.0101 0.0125 0.0027 Dominant AC+CC vs AA -0.28 (-0.46 to -0.10) 
    CYP2D6    
CYP2D6*1xN PANSSP 0.0302 0.0148 0.0091 Dominant XX+IX vs II -0.60 (-1.05 to -0.15) 
 PANSSG 0.0374 0.0233 0.0118 Dominant XX+IX vs II -0.44 (-0.77 to -0.10) 
rs3892097 
(*4) 
PANSSP 0.0806 0.0281 0.0281 Additive A Each A allele 0.26 (0.03 to 0.49) 
PANSSP: Positive symptoms total; PANSSN: Negative symptoms total; PANSSG: General psychopathology total; PANSST: Total score for all questions; X: gene considered as duplicated; I: gene 
considered as wild-type 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 4: Results 
43 
 
Haplotype analyses were also performed for COMT and DRD2, as well as for the genes showing 
nominal associations (P ≤ 0.05) in Table 12 for HTR2A, CYP1A2 and CYP2D6. LD plots for COMT 
and DRD2 are presented in Appendix G. Due to the large number of SNPs present in COMT, 
haplotype analyses including all the variants genotyped in this gene could not be performed for 
association testing. For this reason, a smaller region was therefore selected for haplotype analysis. 
This region included the SNPs that showed significant associations from the mixed model repeated 
measures analyses performed previously (rs2020917-rs737865-rs6269-rs4633-rs9332377). The 
haplotypes displaying significant associations with changes in PANSS scores and their corresponding 
effect sizes are shown in Table 14. The results of the full analyses are shown in Appendix E3. Three 
main haplotypes were examined for the five investigated SNPs, two of which were associated with a 
poor treatment outcome for PANSS negative scores (AAACT and CAGCT haplotypes). One of these 
haplotypes (CAGCT) was also associated with a poor treatment outcome for PANSS total scores. The 
third haplotype was associated with an improvement in PANSS positive scores (GAATC haplotype) 
after the twelve months. Further analyses for haplotypes demonstrating nominal associations from 
Table 12 (P ≤ 0.05) are shown in Table 15. 
Table 14. COMT haplotype associations with percentage change in PANSS scores, estimating effect sizes 
rs2020917 rs737865 rs6269 rs4633 rs9332377 Frequency Phenotype 
P-
value 
% Change per week (95% CI) 
A A A C T 0.03 PANSSN 0.003 0.2 (0.6 to 1.0) 
C A G C T 0.07 PANSSN <0.000 0.3 (0.5 to 0.8) 
     
 
PANSST 0.006 0.1 (0.3 to 0.6) 
G A A T C 0.02 PANSSP 0.003 -6.4 (-3.9 to -1.4) 
 
 
DRD2 haplotypes, using the significant associations of regions identified previously, did not reveal 
any associations with changes in PANSS scores that were significant (P ≤ 0.01). However, one 
haplotype, HTR2A.CA (rs6311-rs6313) was shown to be significantly associated with PANSS general 
scores and improved treatment outcome. Effect sizes for haplotypes that met the P ≤ 0.01 cut-off are 
shown in Table 15. 
Table 15. Haplotype associations with percentage change in PANSS scores, estimating effect sizes of nominal 
associations 
Haplotype Phenotype P-value % Change per week (95% CI) 
HTR2A.CA PANSSG 0.0030 -0.67 (-1.10 to -0.23) 
 PANSST 0.0104 -0.55 (-0.98 to -0.13) 
CYP1A2.GC PANSSN 0.0125 -0.18 (-0.31 to -0.04) 
CYP2D6.IIADI PANSSP 0.0131 0.35 (0.07 to 0.62) 
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5 CHAPTER 5: DISCUSSION 
Schizophrenia poses a great socio-economic burden in SA and SA populations are understudied with 
regards to pharmocogenetic research of psychiatry (Dodgen et al., 2013; de Wet et al., 2015). This 
study was aimed at investigating polymorphisms in several pharmacogenes identified from the 
literature (COMT, CYP1A2, CYP2D6, DRD2, DRD3, HTR2A and SOD2) in a SA FES cohort. In 
addition, the variation present in these genes was further examined by identifying novel functionally 
relevant variants within these pharmacogenes by using exome data from a previous study performed 
by Drogemöller et al. (2014a). Variants selected for the study were then genotyped in the FES cohort 
and minor allele frequencies (MAF) were compared to other worldwide populations. Lastly, variants 
were evaluated for association with treatment outcomes by looking at changes in PANSS scores 
across twelve months (adjusting for age, gender, ethnicity and baseline PANSS scores). Thus, this 
study played an important role in both the characterization of the variation present in antipsychotic 
pharmacogenes in a South African population, while also determining the relevance of these variants 
for antipsychotic pharmacogenetics applications.  
5.1 Study Design 
A number of drawbacks have been reported with regards to the implementation of pharmacogenetic 
studies of antipsychotic medication to identify genetic variants that are of relevance to the clinical 
context (refer to Table 1). These include poor replication of findings, lack of significant associations, 
clinical heterogeneity and low contribution of single-marker genetic variants (Zhang and Malhotra, 
2013). Hence, comprehensive study designs need to be implemented to advance the field of 
antipsychotic pharmacogenetics in order to overcome these issues. Taking all these considerations 
into account, this study utilized a well-defined FES cohort and although the cohort was relatively 
small, comprising of only 103 individuals, it has some important advantages for pharmacogenetic 
research. The value of this cohort in terms of pharmacogenetic research is emphasized by the lack of 
confounding factors, such as inconsistencies in diagnosis and course of illness, which are eliminated 
by the fact that the individuals in the cohort are experiencing their first episode of psychosis. In fact it 
has been reported that a 50% greater effect size was observed for the association of the DRD2 
polymorphism, rs17997323, with antipsychotic treatment response in patients experiencing their first 
episode of schizophrenia when compared to chronic patients (Zhang et al., 2010). Additional benefits 
of the use of this cohort include the elimination of the effects of prior antipsychotic drug exposure for 
majority of the patients, and due to the fact that these patients receive their medication via injection, 
reliable and accurate results regarding adherence can be obtained for this study.  
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5.2 Genetic Variation Contributing to Schizophrenia Treatment in SA  
This study investigated variants within seven pharmacogenes identified from literature that have 
previously been shown to be implicated in schizophrenia pharmacogenetics within the past five years. 
Novel functional variants in the candidate pharmacogenes were identified from previously generated 
exome data and were included in the study. Prioritized variants were genotyped and assessed to 
distinguish unique genetic profiles in SA populations. To our knowledge, this is the first study to 
provide frequency data for these variants in a unique South African FES population, including many 
patients from the SAC population. Thus, these data have provided valuable information pertaining to 
schizophrenia pharmacogenetic research in the context of South Africa.  
Genetic Variation between SA and Worldwide Populations 
When the MAFs of the investigated variants in the SA populations were compared to other 
populations, most of the MAF showed a similar pattern across populations. Populations with similar 
ancestry had approximately similar frequencies while admixed populations displayed intermediate 
frequencies between populations (Table 10). For instance, the FES Caucasian and European 
populations showed similar frequencies, as well as the FES Xhosa and African populations, as would 
be expected. This trend is illustrated in Figure 6 using COMT rs4680 as an example.  
 
 
Figure 6. Minor allele frequency comparisons of COMT rs4680, between different populations in the SA cohort and 
populations from the 1000 Genomes Project 
As seen in the case of COMT rs4680, SA Caucasians and Europeans displayed similar frequencies for 
the variant (A) allele (50%). This allele was shown to be less prevalent in populations with African 
ancestry (20-30%). The SAC displayed intermediate frequencies between the other two SA 
populations (~40%), as did the admixed Americans between Europeans and Africans. Investigating 
the frequencies of the COMT rs4680 SNP in previous studies revealed that this low activity A allele 
(Met) have been shown to occur from as low as 1% in South Americans to as high as 62% in 
SA FES Cohort 1000 Genomes Project 
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European and South-western Asians, where the high activity Val allele was associated with 
dysfunctional frontal cognition due to high levels of dopamine (Gupta et al., 2009). The high 
variability of this functionally relevant variant in global populations further supports the evidence that 
different ethnic groups may exhibit distinctive genetic variation patterns in genes of relevance to 
pharmacogenetics. This once again highlights the value of performing studies which examine the 
diverse populations residing within South Africa. 
Although the abovementioned pattern of variation was observed for the majority of SNPs investigated 
in this study, the admixed populations did not exhibit intermediate allele frequencies for all variants 
examined. With regards to DRD2 rs1079597, the SAC and AMR exhibited a much higher MAF when 
compared to the other populations, most likely due to Asian contributions as the Asian population had 
the highest MAF of 41%. These frequencies obtained for the FES SAC seem to be plausible due to the 
Asian ancestry components that they carry, which have been described by Daya et al. (2013). 
However, FES Xhosa and Caucasian frequencies are derived from very small sample sizes and are 
therefore not the most accurate representations in all cases.  
An additional important consideration in terms of differences between populations groups is 
differences in the patterns of LD. The commonly studied HTR2A SNPs in pharmacogenetic research 
for schizophrenia, rs6313 and rs6311 have been reported to be in complete LD (Ghadirivasfi et al., 
2011; Reynolds et al., 2014). However, our results reported differences in MAF between these two 
SNPs in the FES SAC and Xhosa populations, as well as the 1000 Genomes African and American 
populations (Figure 7). The rest of the populations showed identical MAFs for both of these SNPs. 
This suggests that these SNPs are only in perfect LD in European and Asian populations, but are not 
in perfect LD in populations of African descent. This is not unexpected, as individuals with African 
ancestry have lower LD compared to the other worldwide populations due to the fact that these 
populations are more ancient and have thus had more time for recombination to occur and LD to 
diminish over time (McEvoy et al., 2011). Careful consideration therefore needs to be given when 
investigating these SNPs in populations of African descent because assuming LD can result in 
inaccurate allele assignment, and tag SNPs for Caucasian studies may not be applicable in African 
studies.   
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Figure 7. Minor allele frequency comparisons of HTR2A rs6313 and rs6311, between different populations in the SA 
cohort and populations from the 1000 Genomes Project 
Rare and Unique Genetic Variation Profiles in SA 
Novel functional exonic variants were identified in COMT and SOD2 in our cohort (Table 9). The 
novel SNP in COMT (rs373611092) occurred in the SAC population. Only one individual carried this 
mutation and was heterozygous for this SNP, hence limiting its implementation for current 
pharmacogenetic applications. The SNP thus had a frequency of 1% in the SAC population and was 
predicted by PolyPhen-2 to have probable damaging effects on the translated product as it results in a 
missense mutation, Met90Val, being situated approximately 1000 bp downstream from rs4680. The 
novel missense mutation in SOD2, rs372173830, results in the Glu133Asp substitution, and was 
predicted in silico as benign or tolerated to the resulting protein by Polyphen-2 and SIFT algorithms, 
respectively. This variant was detected in heterozygous samples in both our Xhosa (N = 1) and SAC 
(N = 8) populations with frequencies of 4% and 5% respectively.  
Possible new CYP alleles may also point to unique patterns of genetic variation that exist in SA. 
However, due to the lack of the reliability of NGS technologies for these genes with high sequence 
similarities, CYP variants were not investigated further (Drögemöller et al., 2013). Previous studies by 
our group, which have utilized specially designed genotyping assays to investigate the variation in the 
CYP genes, have consistently identified novel variants. However, these variants occur at very low 
frequencies and are thus not likely to contribute substantially to antipsychotic treatment response 
outcomes (Gaedigk et al., 2007; Drögemöller et al., 2010; Wright et al., 2010; Drögemöller et al., 
2013). Nonetheless, the presence of novel variants in SA populations highlights the importance of re-
sequencing these under-studied populations as these novel variants could play a potential role in 
pharmacogenetic applications. As more and more rare variation is detected we will improve our 
SA FES Cohort 
1000 Genomes Project 
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capabilities to account for the effects of these variants and prediction algorithms will improve 
(Drögemöller et al., 2014a).  
The CYP2D6 variants that were chosen for genotyping had a higher frequency in our cohort (Table 
11) when compared to the frequencies of populations worldwide retrieved from the Human CYP 
Allele Nomenclature Database (Table 11), which consisted of much larger sample sizes. The presence 
of the duplication (*1xN) and deletion (*5) of CYP2D6 was quite prevalent in our Xhosa sample. 
Conversely, the loss-of-function alleles (*4 and *6) that have been reported to be mostly prevalent in 
Europeans (Sistonen et al., 2009), demonstrated higher frequencies in our small Caucasian cohort 
when compared to the European populations.   
Similar trends are reported on indigenous African populations in a previous study performed by 
Sistonen et al. (2007), by which the South-eastern and South-western Bantu and San populations 
showed a frequency of 18.8% and 14.3% respectively for CYP2D6*5, corresponding with our results. 
These results are also consistent with the results obtained from a later study from the same research 
group that reported a frequency of 12.5% for CYP2D6*5 in a SA Bantu population and frequencies 
ranging between 3.3-6.6% for populations in the rest of the African continent (Sistonen et al., 2009). 
Although this allele is rare in European and Asian populations, it is quite evident that this allele is 
more prevalent in African populations, specifically Southern African populations.  
Other CYP2D6 alleles in our cohort were also compared with the frequencies observed in other 
studies in SA populations, i.e. Xhosas by Wright et al. (2010) and SACs and Caucasians by Gaedigk 
and Coetsee (2008) (Figure 8). These frequencies demonstrate CYP2D6*5 to be quite prevalent in 
populations with a large African component and CYP2D6*4 with European components. Frequencies 
for CYP2D6*1xN also seem to be more prevalent in African populations but Gaedigk and Coetsee 
(2008) did report a small proportion presented (0.3%) in their Caucasian cohort. Although the same 
trend is seen with variants in the same population group, some proportions differ slightly, most likely 
due to the size of the cohorts and therefore this still needs further investigation in larger cohorts. 
Discrepancies between the frequencies observed in SA cohorts and those of the 1000 Genomes 
Project which has indexed the human variome by the utilization of next-generation sequencing, could 
be a result of CYP2D6’s inability to sequence well. Drögemöller et al. (2013) has demonstrated that 
variation in CYP genes cannot be well captured by these NGS technologies due to genomic 
complexities of GC rich regions, high sequence similarities and presence of pseudogenes. Although 
NGS technologies have remarkably advanced the field of pharmacogenetics and pharmacogenomics, 
alternative genotyping strategies are still required for capturing unique variation in complex 
pharmacogenes, such as CYP2D6. Improvement in these NGS technologies will also be required to 
address the current shortcomings.  
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Inferring CYP2D6 Metabolizer Phenotypes using the AS Model 
It is important to consider the overall CYP2D6 activity by comparing all the alleles in conjunction to 
establish metabolizer phenotype profiles. Hence, the AS is an important parameter to consider when 
investigating the combined effect of all allele-defining variants.  An AS of 0 is denoted by individuals 
characterized as PMs and an assigned value greater than 2 is an indication of UM since the individual 
would carry a functional allele together with a functional duplication of the gene (Gaedigk et al., 
2007). Population sizes for our Caucasian and Xhosa samples were too small to accurately infer 
metabolizer phenotypes using the AS. Examination of the SAC population revealed that 5% of this 
cohort were PMs (Figure 5). Interestingly, Dandara et al. (2001) also found PMs to occur at low 
frequencies in the SA Venda population (2.6%) due to the presence of the non-functional CYP2D6*4 
allele, and a PM frequency of 2.3% in psychiatric Tanzanian patients accounted by the prevalence of 
the reduced function CYP2D6*17 allele, which was not genotyped in our cohort. This study reported 
that populations closely related to the Bantu tribes in SA were likely to exhibit similar frequencies of 
PMs, which was confirmed by the current study. Frequencies for UMs in the SACs were shown to 
occur at 4%, which is consistent with frequencies of 5% for this same population in the study by 
Gaedigk and Coetsee (2008).  
The majority of individuals from our cohort belonged to the IM/EM category (35-56%) (Figure 5). 
The AS association study should however be replicated in a larger cohort by comparing interethnic 
frequencies for the CYP2D6 alleles and improving classification of these variants in order to 
document the different frequencies observed between populations groups. Treatment dosages can 
therefore be optimized once the AS is calculated and patients will be better identified by their relative 
metabolizing phenotypes and be treated accordingly. By adapting treatment dosages, a more desirable 
treatment outcome can be achieved for PMs and UMs since deficient treatment regimens can be 
eliminated. For instance, PMs will need dose reductions of about 50-70% for FGAs and 
antidepressants, where UMs will need adjustments of up to 150% due to its rapid clearance, usually 
making these patients non-responsive to the medication and also resulting in toxic adverse effects 
(Swen et al., 2011). However, no association with the AS and treatment response was observed in this 
study, most likely due to the fact that not all alleles were examined. Additionally, CYP2D6 may be 
more involved in toxicity (Teh and Bertilsson, 2012), which was not examined in this study, than 
efficacy. Borges et al. (2010) implemented the AS model in a study to predict CYP2D6 metobolizer 
phenotypes to tamoxifen response. They reported the AS to be twice as effective in predicting the 
exposure to drugs, but also showed that concomitant treatment seems to confound the prediction using 
this system. Implementation of the AS system to predict phenotype outcome will be of a great 
advantage within the clinical setting if CYP2D6 variation is well elucidated, but it is also important to 
consider factors that are involved in drug exposure, which will influence the predicted phenotype.  
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Figure 8. Minor allele frequency (%) comparisons for CYP2D6 variants between the SA FES cohort and different Southern African populations obtained from literature  
 
Gaedigk and Coetsee (2008) Wright et al., 2010 
SA FES Cohort 
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5.3 Significant Associations of Pharmacogene Variation and Antipsychotic Treatment 
Response 
A huge concern with antipsychotic treatment of schizophrenia is that the medication is only 
effective in ~50% of the patients (Lohoff and Ferraro, 2010). Trial and error methods have been 
used to treat schizophrenia patients, which have resulted in poor treatment administrations due to 
the inter-individual variation presented in treatment response profiles (Gardner et al., 2014). 
Understanding these variations and studying symptom categories separately can allow patients to 
be grouped in a more homogenous manner than the conventional DSM-5 method, whilst 
recognizing that the polymorphisms associated with treatment outcome can direct the 
establishment of improved treatment and management. As a result this could eventually lessen the 
communal burdens associated with mental health systems that SA is currently faced with.  
Aberrant neurotransmission circuitries have shown evidence for being involved in the 
pathophysiology of schizophrenia (Lisman et al., 2008), highlighting the importance in 
understanding the complex networks affecting brain function on which antipsychotic medication 
target to alleviate psychotic symptoms. This study investigated a large amount of variation using 
several genotyping strategies to examine the contribution of genetics in the context of a well-
characterized cohort of SA FES patients. This study therefore demonstrated the important roles of 
COMT and DRD2 with regards to PANSS negative scores and treatment outcome. These findings 
are quite interesting as it fits in well with the dopamine hypothesis and FGAs that act on 
dopamine receptors (Changasi et al., 2014), providing further substantiation with the recognized 
biological mechanism of action in schizophrenia. The most significant associations with 
polymorphisms in these genes varied with regards to (i) direction of response and (ii) effect sizes. 
This once again highlights the complexity of antipsychotic treatment response outcomes. Figure 9 
gives an indication of the genetic variants playing a role in the treatment of negative symptoms 
each week, using flupenthixol decanoate after twelve months, with HTR2A and CYP1A2 playing 
more minor roles in the treatment of negative symptoms.  
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Figure 9. Associations with genetic polymorphisms and treatment outcome of negative symptoms after twelve 
months of treatment with flupenthixol decanoate 
The results in this study showed that the COMT gene was significantly associated with the 
treatment of negative symptoms. Our findings suggest the T allele of COMT rs4633 contributes to 
the improvement of negative symptoms [P = 0.0080, ES = -0.17 95% CI (-0.30 to -0.04)]. 
Although the role of the rs4633 SNP is unclear in pharmacogenetics, recent studies have 
commonly investigated this SNP with regards to haplotypes of r4680 and rs4818 which have been 
associated with COMT activity for mental disorders in Europeans and Asians (Htun et al., 2014; 
Li et al., 2014). Wang et al. (2009) reported the T allele for rs4633 to be significantly associated 
with paranoia (P = 0.004) and hallucinations (P = 5.141 x 10
-5
) in paranoid schizophrenic 
patients, possibly induced by the increased COMT expression. In a later study, this same research 
group reported the rs4633-rs4680 haplotype to be associated with an increase in severity of total 
negative symptom scores as well as subcategories of negative symptoms, which included 
affective flattening (P = 0.003), asociality (P = 0.011), apathy (P = 0.007) and emotional 
withdrawal (P = 0.003) (Wang et al., 2010). The rs4633 SNP is a synonymous variant that have 
previously been reported to be in complete LD with rs4680 in Europeans but not Chinese patients 
(Voisey et al., 2012). It has been shown to influence COMT expression that could lead to 
increased COMT activity and hence, decreased dopamine levels (Bray et al., 2003; Nackley et 
al., 2006; Wang et al., 2009). This phenomenon could explain the improvement of negative 
symptoms observed in our study due to the hypo-frontality and decreased dopamine 
neurotransmission (Potkin et al., 2002; Shi et al., 2014). In another study, Gupta et al. (2009) 
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found rs4633 to be significantly associated with a good response to risperidone in schizophrenia 
patients using allelic models [P = 0.036, ES = 1.80 95% CI (1.03-3.15)].  
The COMT rs4680 SNP is very well-studied and often found in literature with regards to genetic 
studies performed on schizophrenia. Our study did not replicate the significant findings that most 
recent pharmacogenetics studies have found regarding its association with treatment outcome in 
schizophrenia even though this SNP was quite prevalent in our cohort and its occurrence 
corresponded with populations worldwide (Figure 6). These previous studies reported significant 
associations with the low activity Met (A) allele and worse treatment outcome of negative 
symptoms for schizophrenia (Pelka-wysiecka et al., 2013; Green et al., 2014; Bosia et al., 2015). 
Wright et al. (2012) also reported the lack of significant associations of COMT rs4680 with 
schizophrenia pathophysiology in a Xhosa cohort highlighting the need to investigate African 
populations independently in pharmacogenetic research in order to develop unique genotyping 
strategies on these populations. The lack of association found for rs4680 by Wright et al. (2012) 
and our study could indicate that the variation in LD in African populations have helped to show 
that rs4633 is rather the causal SNP for African populations (D’ = 1, See Appendix G).  
In contrast to the findings for rs4633, rs9332377 showed allelic associations with worsening of 
negative symptoms after treatment [P = 0.0006, ES = 0.25 95% CI (0.11 to 0.39)] with the T 
allele. Although only limited association studies for schizophrenia pharmacogenetics research are 
available for this SNP, it has previously been reported to be associated with other negative effects 
of treatment outcome, namely cisplatin-induced ototoxicity, presenting more common in Africans 
than Europeans  (Drögemöller et al., 2011; Aminkeng et al., 2014), thus highlighting the role of 
this SNP in developing ADRs with treatment outcome. Nieratschker et al. (2010) also 
investigated rs9332377 in Germans for association with negative symptoms of schizophrenia and 
recruited 631 schizophrenia patients and 207 nuclear families. However, no significant 
associations were detected for this large cohort after correcting for multiple testing. This SNP 
have also been associated with anger in a study investigating suicidal behaviour in Germans and 
Italians (P = 0.03) (Calati et al., 2011), suggesting it may be involved in certain 
psychopathological symptom domains in mental disorders. This SNP also showed an 
involvement with its C allele and worsening of positive symptoms in the COMT.GAATC 
(rs2020917-rs737865-rs6269-rs4633-rs9332377) block; and therefore may be of particular 
relevance to African populations. Further COMT haplotype analyses also revealed improvement 
of PANSS negative scores (Table 14) for two of the haplotype blocks, AAACT and CAGCT by 
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which the latter showed strong associations [P < 0.00, ES = 0.30 95% CI (0.50 to 0.80)]. This 
haplotype block was also associated with improved PANSS total scores. 
Additionally, our study revealed nominal associations with worsening of treatment outcome for 
rs737865 and rs6269 (Table 12), where negative symptoms showed associations with worse 
treatment for the latter (P = 0.0206). Although it is clear that COMT is responsible for the 
degradation of dopamine in the prefrontal cortex (Chen et al., 2004), these results indicate the 
important role that COMT plays in the pathophysiology of schizophrenia, which needs to be well 
elucidated in order to improve treatment outcome. COMT also demonstrates cardinal influence on 
negative symptomology within South African schizophrenia populations. Evidence for this can be 
supported by significant findings from a previous study that utilized a South African Xhosa 
population and reported significant associations of COMT variation (rs45536341, rs6269 and 
rs4633) with negative symptom severity and suggests that variants in LD within this gene, 
specifically in the P2 promoter region, play a role in negative symptom severity in African 
populations (Wright et al., 2012). This relates to our findings which show the involvement of 
COMT variation with negative symptoms in SA populations. 
Dopamine receptors play a fundamental role in the regulation of neural circuitries responsible for 
the pathological symptoms of schizophrenia, which is important to understand in order to develop 
future drug discovery attempts (Howes et al., 2012), especially due to its relevance of being 
targeted by FGAs. Not only were variants in COMT, which is involved in the metabolism of 
dopamine, significantly associated with PANSS negative scores, but our results also pointed 
towards DRD2’s considerable involvement with treatment outcomes for negative symptoms. 
However, the directions of effects for these associations are ambiguous. The commonly studied 
rs1799732 SNP involved in translational activity of the gene (Mi et al., 2011), was shown to 
exhibit both improved and worsening of negative symptoms with genotypic models. The -/C vs 
C/C genotypes showed an improvement to treatment outcome after twelve months [P = 0.0004, 
ES = -0.19 95% CI (-0.38 to 0.00)], where -/- vs C/C genotypes were more strongly associated 
with a worse treatment outcome [P = 0.0004, ES = 0.50 95% CI (0.15 to 0.86)]. A meta-analysis 
study conducted by Zhang et al. (2010) reported six studies (N = 698) to show a worse 
antipsychotic treatment outcome for del carriers compared to C/C (P = 0.03), concluding that del 
carriers contributed to a worse outcome, which is in line with what was observed for homozygous 
del individuals, but not heterozygous individuals. Additionally, the fact that the del allele has 
been reported in the literature to be associated with a poorer treatment response (Arranz et al., 
2013) further supports the need to investigate this variant in more SA populations to determine 
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the exact role that this variant plays in antipsychotic treatment outcomes and larger cohorts are 
needed to tease out the intricacies of the detected association.  
A further significant association was identified for the intronic variant, DRD2 rs1079597, 
involved in decreased D2 receptor density that display irregular dopamine levels in the striatum 
(Vijayan et al., 2007). Our results showed association for rs1079597 with worsening of negative 
symptoms each week after twelve months of treatment [P = 0.0020, ES = 0.93 95% CI (0.34 to 
1.53)]. Recessive models indicated AA vs AG+GG genotypes to contribute to an undesirable 
treatment outcome. In line with these results, unadjusted models also evidently illustrate the 
decline in PANSS negative scores (Figure 10) with the AG+GG genotypes, confirming that the A 
(B2) allele contributes to a poor treatment outcome. A recent study showed that the G (B1) allele 
demonstrated improved treatment outcome of negative symptoms after six weeks of treatment in 
Korean schizophrenia patients using both genotypic (P = 0.017) and haplotype analysis 
(rs1079597-rs1800497: T-C associated with poor response to negative symptoms, P = 4.11 x 
10
−7
, permutated P = 0.014) (Kang et al., 2015). In an earlier study, the variant allele A (B2) was 
associated with better clozapine response in African Americans but the association was absent in 
Caucasians (Hwang et al., 2005). Discrepancies in these findings could be a result of frequency 
and LD variation between different ethnicities, which accounts for inter-individual variation for 
treatment response. The opposing direction of the effects observed in our study may also be 
explained by the different drugs used, since clozapine has a very different mechanism of action as 
compared to flupenthixol decanoate (Zhang and Malhotra, 2013).  
 
Figure 10: DRD2 rs1079597's association with negative symptoms after twelve months of treatment with 
flupenthixol decanoate 
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Additionally, nominal associations have been illustrated with improved treatment outcome for 
negative symptoms in HTR2A (rs6311) and CYPIA2 (rs762551) (P ≤ 0.05) where further 
haplotype investigations unveiled more findings for these genes (Table 15). Variation in the 
HTR2A gene is important in pharmacogenetic research of schizophrenia and plays a role in 
treatment response since many antipsychotics target these receptors that are involved in dopamine 
circuitries (Blasi et al., 2015). In this study, although rs6311 was associated with improved 
negative symptoms after treatment, haplotype analyses of the two SNPs in HTR2A (rs6313-
rs6311) revealed that the CA block showed significant associations to PANSS general (P = 
0.0030) and total (P = 0.0104) scores, also showing an improvement to treatment. This shows 
how HTR2A may be involved in various symptom domains. This also further supports the notion 
that haplotype analyses are necessary for these SNPs because they are not in complete LD in SA 
populations as demonstrated from the MAF results. Chen et al. (2009) performed a study on a 
Han Chinese population suffering from schizophrenia and found that the rs6313-rs6311 haplotype 
with CC/GG genotypes predicted the influence of negative symptoms on treatment outcome with 
aripiprazole. In another study performed on a Caucasian population from Moscow, the CC 
genotype for rs6313 showed to be more prevalent with positive, negative and general symptoms 
in patients suffering from major psychoses (Golimbet et al., 2002). This highlights the role that 
HTR2A plays in regulating drug plasma levels of SGAs, which in turn reduces negative 
symptoms and corresponds with our results depicting how these SNPs affect symptoms in our 
cohort by its improvement after treatment. However, the minor associations found for this gene 
could be related to the smaller role of HTR2A in FGA response (Reynolds et al., 2014).  
CYP1A2 is involved in the metabolism of many antipsychotic drugs and demonstrates a wide 
range of inter-individual variability (Perera et al., 2012). The CYP1A2 rs762551 variant is readily 
inducible and leads to an increased CYP1A2*1F activity which would ultimately lead to 
decreased plasma levels of antipsychotic drugs (Changasi et al., 2014).  In this study, rs762551 
(CYP1A2*1F) was associated with changes in negative symptoms where patients carrying the C 
allele were more inclined towards showing treatment improvement of negative symptoms per 
week after twelve months [P = 0.0027, ES = -0.28 95% CI (-0.46 to -0.10)]. The haplotype block 
containing the C allele, CYP1A2.GC, also showed an improvement with negative symptoms after 
twelve months of treatment [P = 0.0125, ES = -0.18 95% CI (-0.31 to -0.04)], providing further 
evidence of rs762551‘s C allele playing a role in the treatment of negative symptoms.  Similar to 
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our results, Balibey et al. (2011) reported that the A allele was associated with poor clozapine 
response and that AA genotypes were associated with treatment resistance of clozapine.   
This study revealed no associations with treatment outcome for DRD3 and SOD2, and only 
marginal associations with CYP2D6 and changes in positive scores after treatment (Table 12). 
However, further replicative studies are warranted, especially for the nominal associations found 
in this study. Although many of these results did not survive correction for multiple testing, these 
associations are replications of robust findings from previous studies and thus the corroboratory 
evidence provided by this study shows that these variants are likely to be true positive findings, 
especially since this study used a well-characterized cohort. The key finding for this study 
suggests that COMT and DRD2 play vital roles in the treatment of negative symptoms, as these 
genes are crucial in regulating dopamine neurotransmission and further supports the dopamine 
hypothesis, indicating its ideal candidacy in studying and understanding schizophrenia 
pathogenesis and treatment. These findings for COMT and DRD2 are very valuable since 
negative symptoms are generally not well treated by antipsychotic medication (Abou-Setta et al., 
2012). By identifying variants that will improve our understanding of the negative symptom 
domain, we can develop better strategies to treat these symptoms and alleviate ineffective 
treatment regimens. Since SA and many third-world countries still use FGAs to treat patients, 
these countries will strongly benefit from studies like ours that will aid in improving treatment 
with FGAs.  
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6 CHAPTER 6: CONCLUSION 
This study provided important pharmacogenetic data for under-represented populations in South 
Africa, where health care institutes are faced with restricted or inadequate mental health resources 
and services. This study therefore met its aim and objectives by genotyping a large number of 
polymorphisms in several pharmacogenes associated with antipsychotic treatment outcomes in a 
SA FES cohort. Polymorphisms were successfully genotyped for COMT, CYP1A2, CYP2D6, 
DRD2, DRD3, HTR2A and SOD2 in the entire cohort of 103 FES individuals using several 
different genotyping strategies. The allele and genotype frequencies enabled us to distinguish the 
differences between SA populations, particularly the SAC population, and those from African, 
American, East Asian and European populations from the 1000 Genomes Project and the Human 
CYP Allele Nomenclature Database, indicating unique genetic diversity present in SA 
populations. Association analyses were successfully performed to establish if the polymorphisms 
investigated in this study are associated with treatment outcomes by looking at the changes in 
PANSS scores across twelve months of treatment.  
The exome data obtained from a previous study by Drögemöller et al. (2014a) enabled us to 
successfully identify novel variants that were unique to our cohort. These novel functional 
variants in COMT and SOD2 were successfully genotyped in the entire cohort. This highlights the 
unique genetic profile that SA populations have which distinguishes them from populations 
around the world. Successful genotyping strategies were performed for these novel variants and 
they can therefore be further investigated in future studies of SA populations. However, these 
variants occurred at a very low frequency and therefore a lack of significant findings was 
associated with these variants due to reduced statistical power. Although rare variation 
demonstrates evidence for playing a role in treatment response, next-generation sequencing 
technologies should further be advanced to capture these variants as it might demonstrate 
important inferences in future pharmacogenetic research (Drögemöller et al., 2014b).  
Furthermore, the minor allele frequencies for most of the SNPs investigated from our populations 
showed correlation with frequencies in populations from the 1000 Genomes project, where the 
FES Caucasian group was similar to Europeans, and Xhosas similar to Africans, indicating 
evidence of common ancestry. The SAC population showed intermediate frequencies between the 
Caucasians, Africans and Asians, illustrating the contribution from various ancestries and making 
this a unique admixed group that needs careful attention when evaluating their treatment response 
profiles. These frequencies suggest that we need to take into account that studies performed on 
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SA populations should be done independently from other populations because of our unique 
diversity.  
Our data revealed promising evidence for the COMT and DRD2 variants with negative symptoms 
of schizophrenia after antipsychotic treatment. This study successfully identified associations of 
dopaminergic polymorphisms involved in the treatment of negative symptoms of schizophrenia 
symptoms after twelve months of treatment with flupenthixol decanoate. Variation in COMT 
(rs4633) and DRD2 (rs1799732) displayed positive treatment outcomes. It is quite difficult to 
treat negative symptoms and therefore this study provided important data that could unravel clues 
underlying the treatment of negative symptoms. Lack of significant findings for COMT rs4680 in 
both this study and by Wright et al. (2012) further supports unique profiles for SA populations in 
pharmacogenetic research, even though this SNP was observed at similar frequencies to the 
worldwide populations from the 1000 Genomes Project database. This suggests that variation in 
SA populations compared to worldwide populations should be treated differently as they might 
result in differential drug response phenotypes.  
This study has enabled a guideline for researchers to discover clues underlying the intricate nature 
of schizophrenia aetiology in SA populations by enhancing treatment efficacy, which will 
ultimately lead to the improvement of mental health systems. Pharmacogenetic research has been 
advancing in recent years, but further studies need to be performed on these under-studied cohorts 
to aid the facilitation of developing tailored treatment in the future which will show a significant 
improvement of drug efficacy between 10-15% and decrease toxicity between 15-20% (Arranz et 
al., 2013).  
6.1 Limitations and Future Directions 
It is important to incorporate environmental factors into a study since these largely affect the 
outcome of schizophrenia pathophysiology as well (Duan, 2003). Environmental factors can 
include factors like smoking status, alcohol or drug abuse, past traumatic experiences, living 
environment, caffeine consumption, etc. and many of these factors have been implicated in the 
variability of drug response and metabolism of schizophrenia in past studies (Perera et al., 2012; 
Schmitt, 2014). By incorporating these factors into a study, it might be possible to understand the 
mechanism involving the disease progression, aetiology, and inter-individual variability of 
treatment response, and thus finding the link between genetics and the environment will enable us 
to predict treatment outcome more efficiently. Therefore, limitations to this study include the lack 
of investigation of environmental factors as this may help explain the complexity of some of the 
findings, e.g. those associated only with specific genotype classes.  
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This study only focused on a number of pharmacogenes important for antipsychotic medication 
and a more comprehensive list is reported by Arranz and de Leon (2007), Foster et al. (2010) and 
Kohlrausch (2013). Drögemöller et al. (2013) investigated pharmacogenetic variation in South 
African populations, and also provides a list of  important genes involved in antipsychotic 
medication. All variants contributing to antipsychotic efficacy is, however, not yet known and 
future prospective studies may identify additional genes that could be screened and investigated. 
As South African populations are both unique and understudied, this study has played an 
important role in providing information to aid in understanding the sequence diversity of SA 
populations in order to overcome the mismanagement of antipsychotic treatment in SA health 
sectors. However, due to the highly polymorphic nature of CYP2D6 alleles, consisting of over 
100 alleles (Sim and Ingelman-Sundberg, 2010), this study only examined a few selected 
clinically relevant alleles. In order to accurately infer the CYP status of patients as it is important 
to take into account all alleles influencing metabolizer phenotypes that will affect the statistical 
significance (Almoguera et al., 2013). As mentioned previously, better genotyping strategies for 
CYP alleles or advancement in sequencing technologies would aid in the development of 
pharmacogenetic applications due to the unique genetic profiles for SA. Due to this unique 
variation, it may be required to sequence SA individuals who do not respond to treatment. A good 
option would be to utilize Sanger sequencing as the data obtained for the 11 FES individuals 
demonstrated the presence of rare novel variants in the SAC population. This option would not 
only be cost-effective in a resource-limited setting as compared to whole genome sequencing, but 
also have the potential to identify rare variants unique to SA individuals (Drögemöller et al., 
2013). 
Other limitations include small cohort sizes, especially for Caucasian and Xhosa patients and to 
date, there is no replicative cohort available for this study. Although this study is in itself a 
replication cohort as the variants investigated in this study have already been previously 
associated with treatment outcomes, further replicative studies are necessary in future to provide 
corroborating evidence for the exact phenotypes investigated in this study. Larger SA cohorts are 
needed, especially for the different ethnicities in order to tease out some of the complexities 
observed with regards to the direction and mode of inheritance of the significant associations. 
Populations should be evaluated separately, such as the various Bantu tribes in SA, Caucasians 
from European ancestry, as well as the highly admixed Coloured population. It is therefore 
recommended to repeat these studies in more SA cohorts.  
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Our study only included a small region for COMT haplotype analyses due to the inability of the 
statistical model to compute a quantitative variable of PANSS scores changes with a large set of 
polymorphisms in this gene and only examined the effects of single genes. Development of 
complex statistical modelling may therefore provide further insight into associations with 
variation in the human genome and phenotypes being assessed. This will also be useful for 
identifying associations with variations across multiple genes and complex biological networks, 
as well as its interaction with environmental factors, that all contribute to the aetiology of 
complex diseases like schizophrenia and subsequent treatment response. 
Pharmacogenetics studies like this one would benefit from investigating a large number of 
variants with treatment response. Again this emphasizes the need for alternative advanced 
genotyping technologies that can generate high-throughput data from genetic sequences. Not only 
will this allow for effective genotyping of complex regions within the genome, but it will also be 
able to give accurate results in a short period of time, making genotyping applications more 
feasible. Ultimately results from these studies could be developed to such a level that a 
pharmacogene SNP array or similar test could be designed that would be unique to the 
populations from SA, having a great advantage for clinicians to treat patients effectively based on 
unique genetic profiles. This research promises to further enhance the field of pharmacogenetics 
by bringing about the revolution for personalized medication for SA individuals and improved 
mental healthcare. Although big international studies like the Psychiatric Genomics Consortium 
(http://www.med.unc.edu/pgc), the International Schizophrenia Consortium 
(http://pngu.mgh.harvard.edu/isc/) and various pharmacogenetic studies are underway in aiming 
to elucidate schizophrenia aetiology and improve treatment, results from this study can provide 
information to these large-scale studies on African populations. This study has played an 
important role in providing much needed information for these under-represented cohorts, 
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Table S 1: Components of all reagents in PCRs 
Preparation of Reagents used for PCR 
TBE Buffer  Cresol Loading Buffer 
Stock: 
    10mg Cresol powder
a

    1ml dH2O 
Loading Buffer: 
    3.4g sucrose
c

    9.5ml dH2O





    85µl dH2O 




1.5% - 4% (w/v) gels: 
    1.5g –  4g Agarose powder
b

    100ml 1x TBE Buffer
a





    108g TRIS
a

     55g Boric Acid
a

     7.44g EDTA
a

     1L dH2O 
1x Buffer: 
    100ml 10x TBE Buffer
a
 
    900ml dH2O 
aReagents supplied by Sigma-Aldrich (Pty) Ltd. 
bReagent supplied by SeaKem® 
cReagent supplied by Merck Chemicals (Pty) Ltd. 
Stellenbosch University  https://scholar.sun.ac.za









Figure S 1: Bi-directional Sanger sequencing for COMT rs373611092
 
Patient 1 (Forward strand) 
Patient 1 (Reverse strand) 
Patient 2 (Forward strand) 





































Figure S 3: TaqMan SNP genotyping results for (A) COMT rs5748489; (B) COMT rs2020917 and (C) DRD2 rs6277 














12 APPENDIX C 
 
Figure S 4: Genotype frequencies of cohort 
Stellenbosch University  https://scholar.sun.ac.za





Figure S 5: Genotype frequencies of cohort
Stellenbosch University  https://scholar.sun.ac.za




13 APPENDIX D 
Table S 2: Probability testing for Hardy Weinberg Equilibrium distribution across different populations in the FES 
cohort 














































































































































































14 APPENDIX E1 
Table S 3: Association tests of P values from mixed model repeated measures analyses between genotyped SNPs 
  PANSSN PANSSP PANSSG PANSST 





rs9617850 0.9240 0.8454 0.6948 0.7585 
rs9606186 0.2171 0.7185 0.5979 0.6065 
rs5748489 0.1238 0.9078 0.3064 0.4049 
rs2075507 0.2831 0.3326 0.1772 0.1931 
rs45551837 0.2662 0.8988 0.5547 0.9112 
rs2020917 0.2011 0.0820 0.1418 0.2362 
rs45536341 0.5113 0.0777 0.8085 0.6735 
rs737865 0.8019 0.0201 0.0423 0.0955 
rs6269 0.0569 0.0433 0.1517 0.0356 
rs4633 0.0293 0.9953 0.2191 0.2984 
rs373611092 0.3912 0.8940 0.9355 0.7659 
rs4818 0.8284 0.0824 0.2029 0.3322 
rs4680 0.1260 0.8180 0.4094 0.6703 
rs9332377 0.0026 0.0861 0.1187 0.0674 
rs165599 0.2318 0.1068 0.8361 0.5637 
     
DRD2 
rs1799732 0.0004 0.7079 0.0759 0.0282 
rs1079597 0.0082 0.6399 0.5887 0.1965 
rs1800497 0.0897 0.4111 0.3465 0.6038 
rs6275 0.2332 0.5723 0.9001 0.8242 
rs6277 0.0580 0.3350 0.2420 0.1140 
     
DRD3 
rs6280 0.5276 0.4389 0.2030 0.2688 
     
HTR2A 
rs6311 0.0298 0.2801 0.0842 0.0442 
rs6313 0.5634 0.4290 0.4571 0.3965 
     
SOD2 
rs4880 0.9680 0.6026 0.7806 0.7983 
rs372173830 0.3553 0.0643 0.3806 0.8746 
     
CYP1A2 
CYP1A2*1C 0.3200 0.2882 0.2578 0.3223 




  PANSSN PANSSP PANSSG PANSST 
CYP1A2*1F 0.0101 0.7254 0.1983 0.2226 
     
CYP2D6 
CYP2D6*1xN 0.1698 0.0302 0.0374 0.0689 
CYP2D6*5 0.9191 0.8825 0.7779 0.9284 
CYP2D6*4 0.8657 0.0806 0.8841 0.7872 
CYP2D6*40 0.0992 0.6766 0.3042 0.3541 
CYP2D6*6 0.5481 0.1283 0.8671 0.7293 
CYP2D6_AS 0.0993 0.0539 0.6683 0.7177 
     
Additive Allelic Model 
     
COMT 
rs9617850 (A) 0.8801 0.5680 0.5391 0.6438 
rs9606186 (C) 0.1158 0.8455 0.5841 0.4908 
rs5748489 (A) 0.0611 0.6647 0.1830 0.2479 
rs2075507 (G) 0.1550 0.7239 0.3336 0.2397 
rs45551837 (A) 0.9687 0.8846 0.4437 0.6983 
rs2020917 (T) 0.0767 0.2063 0.5413 0.6283 
rs45536341 (T) 0.5113 0.0777 0.8085 0.6735 
rs737865 (G) 0.6390 0.0495 0.7369 0.4873 
rs6269 (G) 0.0383 0.1124 0.0572 0.0247 
rs4633 (T) 0.0080 0.9516 0.3482 0.1769 
rs373611092 (G) 0.3912 0.8940 0.9355 0.7659 
rs4818 (G) 0.5889 0.2814 0.4538 0.5582 
rs4680 (A) 0.1275 0.9884 0.4457 0.3750 
rs9332377 (T) 0.0006 0.9638 0.3841 0.1174 
rs165599 (G) 0.3669 0.0921 0.5502 0.2836 
     
DRD2 
rs1799732 (del) 0.4642 0.5848 0.4816 0.5140 
rs1079597 (A) 0.1131 0.3637 0.4140 0.1935 
rs1800497 (A) 0.3472 0.6946 0.4274 0.3419 
rs6275 (C) 0.9496 0.5810 0.8181 0.7294 
rs6277 (T) 0.1110 0.7450 0.2620 0.2190 
     
DRD3 
rs6280 (A) 0.2978 0.3778 0.0752 0.1076 
     
HTR2A 
rs6311 (A) 0.0975 0.3204 0.1032 0.1268 
rs6313 (T) 0.3021 0.6792 0.5391 0.5182 
     
SOD2 
rs4880 (C) 0.8038 0.4620 0.6876 0.6712 




  PANSSN PANSSP PANSSG PANSST 
rs372173830 (G) 0.3553 0.0643 0.3806 0.8746 
     
CYP1A2 
CYP1A2*1C (A) 0.6200 0.1251 0.9685 0.7695 
CYP1A2*1F (C) 0.0125 0.5648 0.0952 0.1107 
     
CYP2D6 
CYP2D6*1xN 
(duplication) 0.5831 0.0148 0.0233 0.0617 
CYP2D6*5 (deletion) 0.6859 0.6392 0.9946 0.8149 
CYP2D6*4 (A) 0.6003 0.0281 0.9670 0.5438 
CYP2D6*40 (ins) 0.0992 0.6766 0.3042 0.3541 
CYP2D6*6 (del) 0.5481 0.1283 0.8671 0.7293 
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Table S 4: Associations of the significantly associated variants examining the “best fit” inheritance models estimating 
percentage change in PANSS scores after adjusting for covariates 
  P-value   % Change 
SNP Outcome Genotype Allelic "Best"  Comparison per week (95% CI) 
COMT 
rs737865 PANSSP 0.0201 0.0495 0.0092 Dominant AG+GG vs AA 0.32 (0.08 to 0.56) 
 PANSSG 0.0423 0.7369 0.0423 Genotype AG vs AA 0.19 (0.00 to 0.39) 
      GG vs AA -0.18 (-0.50 to 0.15) 
rs6269 PANSSN 0.0569 0.0383 0.0206 Recessive GG vs AA+AG 0.34 (0.05 to 0.63) 
 PANNSP 0.0433 0.1124 0.0126 Recessive GG vs AA+AG 0.48 (0.10 to 0.86) 
 PANNST 0.0356 0.0247 0.0126 Recessive GG vs AA+AG 0.35 (0.07 to 0.62) 
rs4633 PANSSN 0.0293 0.0080 0.0080 Additive T Each T allele -0.17 (-0.30 to -0.04) 
rs9332377 PANSSN 0.0026 0.0006 0.0006 Additive T Each T allele 0.25 (0.11 to 0.39) 
DRD2 
rs1799732 PANSSN 0.0004 0.3669 0.0004 Genotype DI vs II -0.19 (-0.38 to 0.00) 
      DD vs II 0.50 (0.15 to 0.86) 
 PANNST 0.0282 0.4642 0.0160 Recessive DD vs DI+II 0.39 (0.07 to 0.72) 
rs1079597 PANSSN 0.0082 0.1131 0.0020 Recessive AA vs AG+GG 0.93 (0.34 to 1.53) 
HTR2A 
rs6311 PANNSN 0.0298 0.0975 0.0170 Dominant AA+AG vs GG -0.22 (-0.40 to -0.04) 
 PANNST 0.0442 0.1268 0.0258 Dominant AA+AG vs GG -0.19 (-0.37 to -0.02) 
CYP1A2 
rs762551 PANNSN 0.0101 0.0125 0.0027 Dominant AC+CC vs AA -0.28 (-0.46 to -0.10) 
CYP2D6 
CYP2D6*1xN PANNSP 0.0302 0.0148 0.0091 Dominant XX+IX vs II -0.60 (-1.05 to -0.15) 
 PANNSG 0.0374 0.0233 0.0118 Dominant XX+IX vs II -0.44 (-0.77 to -0.10) 
CYP2D6*4 PANNSP 0.0806 0.0281 0.0281 Additive A Each A allele 0.26 (0.03 to 0.49) 
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Table S 5: Association tests of P values from mixed model repeated measures analyses between haplotypes 
Haplotype PANSSN PANSSP PANSSG PANSST 
DRD2.DAACC 0.6326 0.0418 0.3978 0.1850 
DRD2.DGACC 0.3800 0.4153 0.2799 0.3094 
DRD2.DGATC 0.9438 0.7990 0.7775 0.8267 
DRD2.DGGCC 0.5138 0.9089 0.8416 0.6929 
DRD2.DGGCT 0.0007 0.9027 0.2150 0.0803 
DRD2.DGGTC 0.4171 0.8750 0.3014 0.5264 
DRD2.IAACC 0.1374 0.9410 0.5268 0.3665 
DRD2.IGACC 0.9416 0.3373 0.0513 0.1748 
DRD2.IGACT 0.1828 0.0514 0.5474 0.1926 
DRD2.IGATC 0.9903 0.9947 0.6981 0.7969 
DRD2.IGGCC 0.5106 0.3274 0.5565 0.6588 
DRD2.IGGCT 0.1983 0.6462 0.6902 0.6153 
DRD2.IGGTC 0.4999 0.4995 0.2205 0.3206 
HTR2A.CA 0.0583 0.1047 0.0030 0.0104 
HTR2A.CG 0.0910 0.3653 0.1124 0.1359 
HTR2A.TA 0.2839 0.6299 0.4842 0.4659 
HTR2A.TG 0.3607 0.6484 0.9096 0.8476 
SOD2.CC 0.6673 0.8080 0.6002 0.6978 
SOD2.CG 0.6150 0.1274 0.7614 0.8795 
SOD2.TC 0.9945 0.2829 0.9274 0.7664 
SOD2.TG 0.2992 0.1824 0.2329 0.6220 
CYP1A2.AA 0.6200 0.1251 0.9685 0.7695 
CYP1A2.AC 0.1331 0.5738 0.8503 0.4034 
CYP1A2.GA 0.0354 0.5053 0.0876 0.0660 
CYP1A2.GC 0.0125 0.5648 0.0952 0.1107 
CYP2D6.IDADI 0.2333 0.0922 0.7380 0.2267 
CYP2D6.IDGDI 0.4144 0.2878 0.9321 0.5241 
CYP2D6.IIADI 0.5070 0.0131 0.6548 0.3979 
CYP2D6.IIGDD 0.5539 0.1241 0.8439 0.7137 
CYP2D6.IIGDI 0.3537 0.8465 0.2282 0.4001 
CYP2D6.IIGII 0.0969 0.6788 0.3080 0.3544 
CYP2D6.XDGDD 0.4360 0.8887 0.8356 0.8329 
CYP2D6.XDGDI 0.4360 0.8887 0.8356 0.8329 
CYP2D6.XIADI 0.0768 0.0204 0.0169 0.0093 
CYP2D6.XIGDI 0.2522 0.0373 0.0647 0.1788 
 
 





Table S 6. Association tests of P values from mixed model repeated measures analyses for COMT haplotypes 
rs2020917 rs737865 rs6269 rs4633 rs9332377 Frequency PANSSP PANSSN PANSST PANSSG 
A A A C C 0.04 0.507 0.483 0.247 0.181 
A A A C T 0.03 0.277 0.003 0.036 0.083 
A A A T C 0.09 0.606 0.372 0.509 0.567 
A A G C C 0.02 0.451 0.275 0.188 0.145 
A A G C T 0 0.679 0.007 0.02 0.01 
A G A C C 0 0.848 0.191 0.345 0.343 
A G A T C 0.01 0.081 0 0.002 0.016 
A G A T T 0.01 0.556 0.337 0.791 0.673 
A G G C C 0.05 0.279 0.753 0.341 0.282 
A G G C T 0.01 0.352 0.051 0.209 0.51 
C A A C C 0.09 0.275 0.544 0.713 0.705 
C A A C T 0.01 0.314 0.539 0.352 0.47 
C A A T C 0.25 0.449 0.017 0.547 0.908 
C A G C C 0.02 0.677 0.973 0.819 0.809 
C A G C T 0.07 0.438 0 0.006 0.015 
C G A C C 0.01 0.404 0.679 0.952 0.868 
G A A C C 0.04 0.077 0.261 0.742 0.935 
G A A C T 0.01 0.056 0.537 0.094 0.088 
G A A T C 0.02 0.003 0.685 0.053 0.291 
G A A T T 0.01 0.018 0.458 0.006 0 
G A G C C 0.03 0.144 0.063 0.116 0.253 
G A G C T 0.01 0.002 0.346 0.013 0.026 
G G A C C 0.01 0.481 0.233 0.966 0.711 
G G A C T 0.01 0.224 0.832 0.375 0.367 
G G A T C 0.02 0.025 0.078 0.225 0.777 
G G G C C 0.08 0.077 0.178 0.484 0.378 
G G G C T 0.01 0.946 0.087 0.527 0.911 
T G A C C 0.02 0.608 0.15 0.31 0.506 
T G A C T 0 0.136 0.053 0.005 0 
T G G C T 0.01 0.93 0.236 0.84 0.187 
 
All haplotypes with a frequency ≤ 1% were excluded from further analyses. 
















































































Figure S 6: Significant associations for percentage change in PANSS scores for each SNP after twelve 
months of treatment 






















Figure S 8: DRD2 LD plots for the entire FES cohort presenting (A) D' and (B) r2 values. 
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